MEK inhibitors
Novel MEK inhibitors with specific functional groups for ADCs address the toxicity issues of existing MEK inhibitors, providing improved efficacy and targeted cancer treatment.
Patent Information
- Application Number
- PCT/US2026/028365
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Existing MEK inhibitors, such as trametinib, binimetinib, selumetinib, and cobimetinib, are associated with dose-limiting toxicities and are challenging to develop as payloads for antibody drug conjugates (ADCs) due to the need for balancing multiple aspects, including payload properties.
Development of novel MEK inhibitors with specific functional groups amenable to linking with monoclonal antibodies through cleavable or non-cleavable linkers, suitable for use in ADCs, which exhibit targeted in vivo release to treat cancers associated with MAPK/ERK pathway dysregulation.
The novel MEK inhibitors demonstrate improved efficacy and therapeutic indices, reducing toxicity and enhancing targeted delivery to cancerous tissues.
Smart Images

Figure US2026028365_19112026_PF_FP_ABST
Abstract
Description
MEK INHIBITORSTECHNICAL FIELD
[0001] The present disclosure relates to mitogen- activated protein kinase (MEK) inhibitors, pharmaceutical compositions including the MEK inhibitors, methods of using the MEK inhibitors for the treatment of disease, and methods of making the MEK inhibitors.BACKGROUND
[0002] The mitogen-activated protein kinase (MAPK) / extracellular signal-regulated kinase (ERK) signaling pathway relays extracellular stimuli to the nucleus, thereby regulating diverse cellular responses including cell proliferation, differentiation, and apoptosis.Dysregulation of the MAPK / ERK pathway has been implicated in various cancers, including lung, pancreas, skin, and colon cancer. Mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2, also referred to as MAPKK1 and MAPKK2, respectively, are members of the MAPK signaling cascade. Inhibition of MEK is a strategy to block cell proliferation and induce apoptosis in cancers associated with MAPK / ERK pathway signaling. Available MEK inhibitors trametinib, binimetinib, selumetinib, and cobimetinib are often associated with dose-limiting toxicities, especially cutaneous toxicities. Many patients undergoing treatment with these inhibitors require dose modification, or interruption or discontinuation of the anti-cancer treatment.
[0003] Antibody drag conjugates (ADCs) provide a targeted therapeutic approach offering the potential to deliver potent cytotoxic agents to cancerous tissues, with the advantage of reduced toxicity. Such oncology treatments generally contain a tumor-targeting antibody conjugated via linker to a releasable cytotoxic payload. ADCs, however, are challenging compounds to develop, which often require balancing multiple aspects, including payload properties. There is a need for MEK inhibitors with improved efficacy and therapeutic indices, and particularly, MEK inhibitors suitable as payloads for inclusion in ADCs.SUMMARY
[0004] In one aspect, the present disclosure provides a compound of formula (I):or a pharmaceutically acceptable salt thereof; whereinR1is hydrogen, C1-C3 alkyl, or C3-C5 cycloalkyl;RA1and RA3are independently selected from halogen;RC1is fluoro or chloro;RC5is hydrogen, halogen, or C1-C3 alkyl;X3is a group of the formula (a), (b), or (c):Z1and Z2are independently selected from O and NH;RX3is hydrogen or C1-C3 alkyl;RX4is hydrogen, C1-C3 alkyl, C1-C3 hydroxyalkyl, or C1-C3 alkoxy-Ci-Cs-alkyl; orRX3and RX4together with the atoms to which they attach form a 5- to 6-membered monocyclic heterocyclyl; andRX5is Ci-Ce hydroxyalkyl, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C3-C10 cycloalkyl, 3-to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, Ce-Cio aryl, 5- to 10-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, C3-C10 cycloalkyl-Ci-Cs-alkyl, 3- to10-membered heterocyclyl-Ci-Cs-alkyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, Ce-Cio aryl-Ci-Cs-alkyl, or 5- to 10-membered heteroaryl-Ci-Ca-alkyl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, and heteroarylalkyl are substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, and heteroarylalkyl are optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, Ci-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl; orRX4and Rx5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-Cs-hydroxyalkoxy-C i-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, and wherein the heterocyclyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, Ci-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl.
[0005] In another aspect, provided herein are methods of using the compounds of formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, to treat cancer. The methods include administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
[0006] In another aspect, provided herein are compounds of formula (I), and pharmaceutically acceptable salts thereof, for use in therapy. Additionally provided herein, are the compounds of formula (I), and pharmaceutically acceptable salts thereof, for use in the treatment of cancer. Also provided herein is the use of compounds of formula (I), or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for treating cancer.DETAILED DESCRIPTION
[0007] The present disclosure provides mitogen-activated protein kinase (MEK) inhibitors of formula (I), and pharmaceutically acceptable salts thereof, as described in the Summary.
[0008] The MEK inhibitors may serve as pay loads of antibody drag conjugates (ADCs). The MEK inhibitors may have one or more of advantageous potency, efflux, clearance, physical stability, chemical stability, or other properties making them suitable as payloads for an ADC. The MEK inhibitors may have one or more functional groups amenable to linking to a monoclonal antibody, for example, through a cleavable or non-cleavable linker. The MEK inhibitors may exhibit suitable in vivo release from an ADC, preferably to specific target tissues or cells for the treatment of disease, such as a cancer associated with dysregulation of the MAPK / ERK pathway.
[0009] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C1-C3 alkyl, preferably methyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C3-C5 cycloalkyl, preferably cyclopropyl.
[0010] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RA1is fluoro. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RA3is iodo. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RA1is fluoro and RA3is iodo.
[0011] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RC1is fluoro. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RC1is chloro.
[0012] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R° is hydrogen, halogen, or methyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rc’’ is hydrogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable saltthereof, RC:>is halogen, preferably fluoro or chloro. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rc5is C1-C3 alkyl, preferably methyl.
[0013] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, RA1is fluoro, and RA3is iodo. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, RA1is fluoro, and RA3is iodo. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C1-C3 alkyl, preferably methyl, RA1is fluoro, and RA3is iodo. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C3-C5 cycloalkyl, preferably cyclopropyl, RA1is fluoro, and RA3is iodo.
[0014] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, RA1is fluoro, RA3is iodo, and RC1is fluoro. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, RA1is fluoro, RA3is iodo, and RC1is fluoro. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C1-C3 alkyl, preferably methyl, RA1is fluoro, RA3is iodo, and RC1is fluoro. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C3-C5 cycloalkyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, and RC1is fluoro.
[0015] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, RA1is fluoro, RA3is iodo, and RC1is chloro. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, RA1is fluoro, RA3is iodo, and RC1is chloro. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C1-C3 alkyl, preferably methyl, RA1is fluoro, RA3is iodo, and RC1is chloro. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C3-C5 cycloalkyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, and RC1is chloro.
[0016] In certain embodiments of a compound of formula (I), or a pharmaceuticallyacceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, and R° is hydrogen, halogen, or methyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, RA1is fluoro, RA3is iodo, RC1is fluoro, and R<is hydrogen, halogen, or methyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C1-C3 alkyl, preferably methyl, RA1is fluoro, RA3is iodo, RC1is fluoro, and Rc5is hydrogen, halogen, or methyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C3-C5 cycloalkyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, and RC:>is hydrogen, halogen, or methyl.
[0017] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, and R° is hydrogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, RA1is fluoro, RA3is iodo, RC1is fluoro, and RC5is hydrogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C1-C3 alkyl, preferably methyl, RA1is fluoro, RA3is iodo, RC1is fluoro, and Rc5is hydrogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C3-C5 cycloalkyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, and RC5is hydrogen.
[0018] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, and Rc’’ is halogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, RA1is fluoro, RA3is iodo, RC1is fluoro, and RC5is halogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C1-C3 alkyl, preferably methyl, RA1is fluoro, RA3is iodo, RC1is fluoro, and Rc5is halogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C3-C5 cycloalkyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, and Rc5is halogen.
[0019] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, RA1is fluoro, RAis iodo, RC1is fluoro, and Rc5is methyl. Tn certain embodiments of a compound of formula (I), or apharmaceutically acceptable salt thereof, R1is hydrogen, RA1is fluoro, RA3is iodo, RC1is fluoro, and RC5is methyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C1-C3 alkyl, preferably methyl, RA1is fluoro, RA3is iodo, RC1is fluoro, and RC5is methyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C3-C5 cycloalkyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, and Rc5is methyl.
[0020] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, RA1is fluoro, RA3is iodo, RC1is chloro, and RC:>is hydrogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, RA1is fluoro, RA3is iodo, RC1is chloro, and R° is hydrogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C1-C3 alkyl, preferably methyl, RA1is fluoro, RA3is iodo, RC1is chloro, and RC5is hydrogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C3-C5 cycloalkyl, preferably cyclopropyl, RA1is fluoro, RAis iodo, RC1is chloro, and Rc5is hydrogen.
[0021] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, RA1is fluoro, RA3is iodo, RC1is chloro, and RC:)is halogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, RA1is fluoro, RA3is iodo, RC1is chloro, and R° is halogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C1-C3 alkyl, preferably methyl, RA1is fluoro, RA3is iodo, RC1is chloro, and RC5is halogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C3-C5 cycloalkyl, preferably cyclopropyl, RA1is fluoro, RAis iodo, RC1is chloro, and Rc5is halogen.
[0022] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, RA1is fluoro, RA3is iodo, RC1is chloro, and RC:>is methyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is hydrogen, RA1is fluoro, RA3is iodo, RC1is chloro, and R° is methyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C1-C3 alkyl, preferably methyl, RA1is fluoro,RA3is iodo, RC1is chloro, and RC5is methyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, R1is C3-C5 cycloalkyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is chloro, and RC5is methyl.
[0023] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (a). In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (a), wherein Z1is O and Z2is O. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (a), wherein Z1is NH and Z2is O. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (a), wherein Z1is O and Z2is NH. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (a), wherein Z1is NH and Z2is NH.
[0024] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (b). In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (b), wherein Z1is O and Z2is O. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (b), wherein Z1is NH and Z2is O. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (b), wherein Z1is O and Z2is NH. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (b), wherein Z1is NH and Z2is NH.
[0025] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (c). In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (c), wherein Z1is O and Z2is O. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (c), wherein Z1is NH and Z2is O. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (c), wherein Z1is O and Z2is NH. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula (c), wherein Z1is NH and Z2is NH.
[0026] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of the formula:
[0027] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula:
[0028] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of formula:
[0029] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is hydrogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C1-C3 alkyl, preferably methyl.
[0030] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4is hydrogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4is C1-C3 alkyl, preferably methyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4is C1-C3 hydroxyalkyl, preferably hydroxyethyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4is C1-C3 alkoxy-C1-C3-alkyl, preferably methoxyethyl.
[0031] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is hydrogen, and RX4is hydrogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is hydrogen, andRX4is C1-C3 alkyl, preferably methyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is hydrogen, and RX4is C1-C3 hydroxyalkyl, preferably hydroxyethyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is hydrogen, and RX4is C1-C3 alkoxy-Ci-C3-alkyl, preferably methoxyethyl.
[0032] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C1-C3 alkyl, preferably methyl, and RX4is hydrogen. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C1-C3 alkyl, preferably methyl, and RX4is C1-C3 alkyl, preferably methyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C1-C3 alkyl, preferably methyl, and RX4is C1-C3 hydroxyalkyl, preferably hydroxyethyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C1-C3 alkyl, preferably methyl, and RX4is C1-C3 alkoxy-Ci-Cs-alkyl, preferably methoxyethyl.
[0033] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX5is Ci-Ce hydroxyalkyl, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C3-C10 cycloalkyl, 3- to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, Ce-Cio aryl, 5- to 10-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, C3-C10 cycloalkyl-Ci-C3-alkyl, 3- to 10-membered heterocyclyl-Ci-C3-alkyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, Ce-Cio aryl-Ci-Cs-alkyl, or 5- to 10-membered heteroaryl-Ci-Ch-alkyl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, and heteroarylalkyl are substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, and heteroarylalkyl are optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, Ci-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl.
[0034] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis Ci-Ce hydroxy alkyl, Ci-Ca-hydroxyalkoxy-Ci-Ci-alkyl, C3-C10 cycloalkyl, 3- to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, phenyl, 5- to 6-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, C3-C10 cycloalkyl-Ci-C3-alkyl, or 3- to 10-membered heterocyclyl-Ci-C3-alkyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, and heterocyclylalkyl are substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-Cs-hydroxyalkoxy-Ci-Cb-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, and heterocyclylalkyl are optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-C3-alkyl.
[0035] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis Ci-Ce hydroxyalkyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rx5is 2-hydroxy ethyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX5is selected from the formula:wherein m is 1, 2, 3, 4, 5, or 6.
[0036] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis selected from the formula:
[0037] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis C1-C3-hydroxyalkoxy-C1-C3-alkyl. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX5is selected from the formula:wherein n is 1, 2, or 3, and o is 1, 2, or 3.
[0038] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis C3-C10 cycloalkyl, 3- to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, Ce-Cio aryl, 5- to 10-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, C3-C10 cycloalkyl-Ci-Cs-alkyl, 3- to 10-membered heterocyclyl-Ci-C3-alkyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, Ce-Cio aryl-Ci-Cs-alkyl, or 5- to 10-membered heteroaryl-Ci-Cs-alkyl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, and heteroarylalkyl are substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-C3-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, and heteroarylalkyl are optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl
[0039] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C3-C10 cycloalkyl, 3- to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, phenyl, 5- to 6-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, C3-C10 cycloalkyl-Ci-C3-alkyl, or 3- to 10-membered heterocyclyl-Ci-C3-alkyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, wherein the cycloalkyl, heterocyclyl, phenyl, heteroaryl, cycloalkylalkyl, and heterocyclylalkyl are substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-C3-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl, heterocyclyl, phenyl, heteroaryl, cycloalkylalkyl, and heterocyclylalkyl are optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy.and C1-C3 alkoxy-Ci-Cs-alkyl.
[0040] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis selected from the formula:wherein Ring D is C3-C10 cycloalkyl, 3- to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, C6-C10aryl, or 5- to 10-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S; RX5ais hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-Cs-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl; each RX5bis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-C1-C3-alkyl; p is 0, 1, 2, or 3; and q is 0, 1, 2, or 3.
[0041] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Ring D is C3-C10 cycloalkyl, 3- to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, phenyl, or 5- to 6-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S; RX:,ais hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, C1-C3-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxy alkylcarbonyl; each RX5bis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-C’3-alkyl; p is 0, 1, 2, or 3; and q is 0, 1, 2, or 3.
[0042] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Ring D is C3-C10 cycloalkyl, 3- to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, phenyl, or 5- to 6-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S; RX:,ais hydroxy or C1-C3 hydroxyalkyl; each Rx5bis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy,C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-C1-C3-alkyl; p is 0, 1, 2, or 3; and q is 0, 1, 2, or 3.
[0043] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Ring D is C3-C10 cycloalkyl or 3- to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S; RX5ais hydroxy or C1-C3 hydroxyalkyl; each Rx5bis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-C3-alkyl; p is 0, 1, 2, or 3; and q is 0, 1, 2, or 3.
[0044] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C3-C10 cycloalkyl substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-Cs-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Ch-alkyl.
[0045] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C3-C10 cycloalkyl substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-Cs-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0046] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C3-C10 cycloalkyl substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl is optionally further substituted by a substituent selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0047] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C3-C10 cycloalkyl substituted by hydroxy or C1-C3 hydroxyalkyl, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl.
[0048] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis C3-C10 cycloalkyl substituted by hydroxy or C1-C3 hydroxyalkyl, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0049] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis C3-C10 cycloalkyl substituted by hydroxy or C1-C3 hydroxyalkyl, wherein the cycloalkyl is optionally further substituted by a substituent selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0050] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis C3-C10 cycloalkyl substituted by hydroxy, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl.
[0051] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof,is C3-C10 cycloalkyl substituted by hydroxy, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0052] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis C3-C10 cycloalkyl substituted by hydroxy, wherein the cycloalkyl is optionally further substituted by a substituent selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0053] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis C3-C10 cycloalkyl substituted by C1-C3 hydroxyalkyl, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl.
[0054] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX5is C3-C10 cycloalkyl substituted by C1-C3 hydroxyalkyl, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independentlyselected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0055] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis C3-C10 cycloalkyl substituted by C1-C3 hydroxyalkyl, wherein the cycloalkyl is optionally further substituted by a substituent selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0056] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis C4-C6 cycloalkyl substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halo thioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl.
[0057] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C4-C6 cycloalkyl substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-Cs-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0058] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RXlis C4-C6 cycloalkyl substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-Ca-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl is optionally further substituted by a substituent selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0059] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis C4-C6 cycloalkyl substituted by hydroxy or C1-C3 hydroxyalkyl, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-C alkyl.
[0060] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C4-C.6 cycloalkyl substituted by hydroxy or C1-C3hydroxyalkyl, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.[00611 In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C4-C6 cycloalkyl substituted by hydroxy or C1-C3 hydroxyalkyl, wherein the cycloalkyl is optionally further substituted by a substituent selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0062] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C4-C6 cycloalkyl substituted by hydroxy, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl.
[0063] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C4-C6 cycloalkyl substituted by hydroxy, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0064] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C4-C6 cycloalkyl substituted by hydroxy, wherein the cycloalkyl is optionally further substituted by a substituent selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0065] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX5is C4-C6 cycloalkyl substituted by C1-C3 hydroxyalkyl, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl.
[0066] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C4-C6 cycloalkyl substituted by C1-C3 hydroxyalkyl, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0067] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is C4-C.6 cycloalkyl substituted by C1-C3 hydroxyalkyl, whereinthe cycloalkyl is optionally further substituted by a substituent selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.[00681 In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is selected from the formula:wherein Rx5ais hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-Cs-hydroxyalkoxy-Ci-C3-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl; each Rx5bis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, Ci-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl; q is 0, 1, 2, or 3; and r is 0, 1, or 2.
[0069] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX5ais hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, C1-C3-hydroxyalkoxy-C1-C3-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl; each RX5bis independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy; q is 0, 1, 2, or 3; and r is 0, 1, or 2.
[0070] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3ais hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, C1-C3-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxy alkylcarbonyl; Rx5bis selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy; q is 0 or 1; and r is 0, 1, or 2.
[0071] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX5ais hydroxy or C1-C3 hydroxyalkyl; each Rx5bis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl; q is 0, 1, 2, or 3; and r is 0, 1, or 2.
[0072] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3ais hydroxy or C1-C3 hydroxyalkyl; each RX5bis independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy; q is 0, 1, 2, or 3; and r is 0, 1, or 2.
[0073] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX5ais hydroxy or C1-C3 hydroxyalkyl; RX5bis selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy; q is 0 or 1; and r is 0, 1, or 2.
[0074] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3ais hydroxy; each Rx5bis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, Ci-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl; q is 0, 1, 2, or 3; and r is 0, 1, or 2.
[0075] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3ais hydroxy; each RX5bis independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy; q is 0, 1, 2, or 3; and r is 0, 1, or 2.
[0076] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3ais hydroxy; RX3bis selected from halogen, C1-C3 alkyl, and Ci-C3 alkoxy; q is 0 or 1; and r is 0, 1, or 2.
[0077] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3ais C1-C3 hydroxyalkyl; each Rx5bis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl; q is 0, 1, 2, or 3; and r is 0, 1, or 2.
[0078] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3ais C1-C3 hydroxyalkyl; each Rx5bis independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy; q is 0, 1, 2, or 3; and r is 0, 1, or 2.
[0079] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3ais C1-C3 hydroxyalkyl; RX5bis selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy; q is 0 or 1; and r is 0, 1, or 2.
[0080] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is selected from the formula:wherein each Rx5bis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and Ci-C3 alkoxy-Ci-Cs-alkyl; q is 0, 1, 2, or 3; and r is 0, 1, or 2. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, each RX5bis independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy; q is 0, 1, 2, or 3; and r is 0, 1, or 2. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3bis selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy; q is 0 or 1; and r is 0, 1, or 2.
[0081] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX3is selected from the formula:
[0082] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis C6-C10aryl, preferably phenyl, substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-Cs-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the Ce-Cio aryl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, Ci-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-C1-C3-alkyl.
[0083] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX5is C6-C10aryl, preferably phenyl, substituted by hydroxy, wherein the Ce-Cio aryl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy,C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl.
[0084] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis C -Cio aryl, preferably phenyl, substituted by hydroxy, wherein the Ce-Cio aryl is optionally further substituted by a substituent selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0085] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rxis selected from the formula:
[0086] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxy alkoxy, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, and wherein the heterocyclyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, Ci-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl.
[0087] In certain embodiments of a compound of formula (I), or a pharmaceuticallyacceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, and wherein the heterocyclyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0088] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-Cs-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, and wherein the heterocyclyl is optionally further substituted by a substituent selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0089] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and RX5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by hydroxy or C1-C3 hydroxyalkyl, and wherein the heterocyclyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-C3-alkyl.
[0090] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by hydroxy or C1-C3 hydroxyalkyl, and wherein the heterocyclyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0091] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by hydroxy or C1-C3 hydroxyalkyl, and wherein the heterocyclyl is optionally further substituted by a substituent selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0092] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and RX5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by hydroxy, and wherein the heterocyclyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-C1-C3-alkyl.
[0093] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by hydroxy, and wherein the heterocyclyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0094] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and RX5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by hydroxy, and wherein the heterocyclyl is optionally further substituted by a substituent selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0095] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substitutedby C1-C3 hydroxyalkyl, and wherein the heterocyclyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-C1-C3-alkyl.
[0096] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by C1-C3 hydroxyalkyl, and wherein the heterocyclyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0097] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by C1-C3 hydroxyalkyl, and wherein the heterocyclyl is optionally further substituted by a substituent selected from halogen, C1-C3 alkyl, and C1-C3 alkoxy.
[0098] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a group of the formula:wherein Rx5cis hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-C3-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl; each Rx5dis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-C1-C3-alkyl; Z3and Z4are each independently selected from C, O, N, and S; s is 0, 1, 2, or 3; and t is 0, 1, or 2; provided at least one of Z3and Z4is C, and further provided that Z4is C when t is 0. It is to be understood that when Z3or Z4is C, that position in the ring may be represented by -CH2-, -C(H)(RX5C)-, -C(H)(Rx5d)-, -C(Rx5d)2-, or -C(Rx5c)(Rx5d)-; and that when Z3or Z4is N, that position in the ring may be represented by -NH-, -N(Rx5c)-, or -N(Rx5d)-; understanding that RX5coccurs once and the number of Rx5dsubstitutions on the heterocyclyl are limited by the s variable.
[0099] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rx5cis hydroxy or C1-C3 hydroxyalkyl; each Rx5dis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl; Z3and Z4are each independently selected from C, O, N, and S; s is 0, 1, 2, or 3; and t is 0, 1, or 2; provided at least one of Z3and Z4is C, and further provided that Z4is C when t is 0.
[0100] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a group of the formula:wherein Rx5cis hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl; each Rx5dis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-C1-C3-alkyl; s is 0, 1, 2, or 3; and t is 0, 1, or 2. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rx5cis hydroxy or C1-C3 hydroxyalkyl; each Rx5dis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-C1-C3-alkyl; s is 0, 1, 2, or 3; and t is 0, 1, or 2.
[0101] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a group selected from the formula:wherein each Rx5dis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and Ci-C3 alkoxy-Ci-C3-alkyl; s is 0, 1, 2, or 3; and t is 0. 1, or 2.
[0102] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a group selected from the formula:
[0103] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a group of the formula:wherein Rx5eis hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, C1-C3-hydroxyalkoxy-C1-C3-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl; each RX5fis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, Ci-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-C1-C3-alkyl; u, v, w, and x are each independently selected from 0, 1, and 2, provided that u+v > 1; and y is 0, 1, 2, or 3.
[0104] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rx5eis hydroxy or C1-C3 hydroxyalkyl; each Rx5fis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl; u, v, w, and x are each independently selected from 0, 1, and 2, provided that u+v > 1; and y is 0, 1, 2, or 3.
[0105] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, u is 0, v is 1, w is 1, and x is 0. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, u is 1, v is 1, w is 0, and x is 0. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, u is 2, v is 1, w is 0, and x is 0.
[0106] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX5eis hydroxy, u is 0, v is 1, w is 1, x is 0, and y is 0. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX5eis hydroxy, u is 1. v is 1, w is 0, x is 0, and y is 0. In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, Rx5eis hydroxy, u is 2, v is 1, w is 0, x is 0, and y is 0.
[0107] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a group selected from the formula:wherein each Rx5fis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and Ci-C3 alkoxy-Ci-Cs-alkyl; u, v, w, and x are each independently selected from 0, 1, and 2, provided that u+v > 1; and y is 0, 1, 2, or 3.
[0108] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a group selected from the formula:
[0109] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, RX4and Rx5together with the nitrogen atom to which they are attached form a group selected from the formula:
[0110] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of the formula:wherein Z1, Z2, RX3, RX4, Rx5a, Rx5b, Rx5c, RX5d, RX5e, RX5f, m, n, o, p, q, r, s, t, u, v, w, x, and y are as defined above.
[0111] In certain embodiments of a compound of formula (I), or a pharmaceutically acceptable salt thereof, X3is a group of the formula:wherein Z1, Z2, and Rx5are as defined above, and z is 1 or 2.|0112| Also provided is a compound of formula (1-1):or a pharmaceutically acceptable salt thereof; wherein R1, RA1, RA3, RC1, Rc5, and X3are as defined above. In certain embodiments of a compound of formula (I- 1), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl.
[0113] Also provided is a compound of formula (1-2):or a pharmaceutically acceptable salt thereof; wherein R1, RA1, RA3, RC1, and X3are as defined above. In certain embodiments of a compound of formula (1-2), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl.
[0114] Also provided is a compound of formula (1-3) or (1-4):or a pharmaceutically acceptable salt thereof; wherein R1and X3are as defined above.In certain embodiments of a compound of formula (1-3) or (1-4), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl.
[0115] Also provided is a compound of formula (I-a), (I-b), or (I-c):or a pharmaceutically acceptable salt thereof; wherein R1, RA1, RA3, RC1, RC5, Z1, Z2, RX3, RX4, and RX3are as defined above.
[0116] Also provided is a compound of formula (I-a-1), (I-b-1), or (I-c-1):or a pharmaceutically acceptable salt thereof; wherein R1, RA1, RA3, RC1, RC5, Z1, Z2, RX3, RX4, and RX3are as defined above.
[0117] Also provided is a compound of formula (I-a-2), (I-b-2), or (I-c-2):or a pharmaceutically acceptable salt thereof; wherein R1, RA1, RA3, RC1, Rc5, Z1, Z2, RX3, and RX4are as defined above; and m is 1, 2, 3, 4, 5, or 6. In certain embodiments of a compound of formula (I-a-2), (I-b-2), or (I-c-2), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl. In certain embodiments of a compound of formula (I-a-2), (I-b-2), or (I-c-2), or a pharmacally acceptable salt thereof, m is 2 or 3. In certain embodiments of a compound of formula (I-a-2), (I-b-2), or (I-c-2), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, and Z2is O. In certain embodiments of a compound of formula (I-a-2), (I-b-2), or (I-c-2), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, orcyclopropyl, preferably cyclopropyl, Z1is O, Z2is O, RXis hydrogen, and RX4is hydrogen or methyl. In certain embodiments of a compound of formula (I-a-2), (I-b-2), or (I-c-2), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, and m is 2 or 3. In certain embodiments of a compound of formula (I-a-2), (I-b-2), or (I-c-2), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, and m is 2 or 3. In certain embodiments of a compound of formula (I-a-2), (I-b-2), or (I-c-2), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, and m is 2 or 3. In certain embodiments of a compound of formula (I-a-2), (I-b-2), or (I-c-2), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is chloro, Rcis hydrogen, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, and m is 2 or 3.[01181 Also provided is a compound of formula (I-a-3), (I-b-3), or (I-c-3):or a pharmaceutically acceptable salt thereof; wherein R1, RA1, RA3, RC1, RC5, Z1, Z2, RX3, and RX4are as defined above; Ring D is C3-C10 cycloalkyl, 3- to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, C6-C10 aryl, or 5- to 10-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S; RX5ais hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, C1-C3-hydroxyalkoxy-C1-C3-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl; each RX5bis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy.and C1-C3 alkoxy-C1-C3-alkyl; p is 0, 1, 2, or 3; and q is 0, 1, 2, or 3. In certain embodiments of a compound of formula (I-a-3), (I-b-3), or (I-c-3), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl. In certain embodiments, p is 0 or 1. In certain embodiments of a compound of formula (I-a-3), (I-b-3), or (I-c-3), or a pharmaceutically acceptable salt thereof, q is 0 or 1. In certain embodiments of a compound of formula (I-a-3), (I-b-3), or (I-c-3), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, and Z2is O. In certain embodiments of a compound of formula (I-a-3), (I-b-3), or (I-c-3), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, Z2is O, RX3is hydrogen, and RX4is hydrogen or methyl. In certain embodiments of a compound of formula (I-a-3), (I-b-3), or (I-c-3), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, and q is 0 or 1. In certain embodiments of a compound of formula (I-a-3), (I-b-3), or (I-c-3), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, and p is 0 or 1. In certain embodiments of a compound of formula (I-a-3), (I-b-3), or (I-c-3), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, p is 0 or 1, and q is 0 or 1. In certain embodiments of a compound of formula (I-a-3), (I-b-3), or (I-c-3), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, RC5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, p is 0 or 1, and q is 0 or 1. In certain embodiments of a compound of formula (I-a-3), (I-b-3), or (I-c-3), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is chloro, RC5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, p is 0 or 1, and q is 0 or 1.
[0119] Also provided is a compound of formula (I-a-4), (I-b-4), (I-c-4), (I-a-5), (I-b-5), (I-c-5), (I-a-6), (I-b-6), or (I-c-6):4041or a pharmaceutically acceptable salt thereof; wherein R1, RA1, RA3, RC1, Rc5, Z1, Z2, RX3, and RX4are as defined above; Rx5ais hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxy alkylcarbonyl; each RX5bis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl; q is 0, 1, 2, or 3; and r is 0, 1, or 2. In certain embodiments of a compound of formula (I-a-4), (I-b-4), (I-c-4), (I-a-5), (I-b-5), (I-c-5), (I-a-6), (I-b-6), or (I-c-6), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl. In certain embodiments of a compound of formula (I-a-4), (I-b-4), (I-c-4), (I-a-5), (I-b-5), (I-c-5), (I-a-6), (I-b-6), or (I-c-6), or a pharmaceutically acceptable salt thereof, q is 0 or 1. In certain embodiments of a compound of formula (I-a-4), (I-b-4), (I-c- 4), (I-a-5), (I-b-5), (I-c-5), (I-a-6), (I-b-6), or (I-c-6), or a pharmaceutically acceptable salt thereof, r is 1. In certain embodiments of a compound of formula (I-a-4), (I-b-4), (I-c-4), (I-a-5), (I-b-5), (I-c-5), (I-a-6), (I-b-6), or (I-c-6), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, and Z2is O. In certain embodiments of a compound of formula (I-a-4), (I-b-4), (I-c-4), (I-a-5), (I-b-5), (I-c- 5), (I-a-6), (I-b-6), or (I-c-6), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, Z2is O, RX3is hydrogen, and RX4is hydrogen or methyl. In certain embodiments of a compound of formula (I-a-4), (I-b-4), (I-c-4), (I-a-5), (I-b-5), (I-c-5), (I-a-6), (I-b-6), or (I-c-6), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, and q is 0 or 1. In certain embodiments of a compound of formula (I-a-4), (I-b-4), (I-c-4), (I-a-5), (I-b-5), (I-c-5), (I-a-6), (I-b-6), or (I-c-6), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, and q is 0 or 1. In certain embodiments of a compound of formula (I-a-4), (I-b-4), (I-c-4), (I-a-5), (I-b-5), (I-c-5), (I-a-6), (I-b-6), or (I-c-6), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, q is 0 or 1, and r is 1. In certain embodiments of a compound of formula (I-a-4), (I-b-4), (I-c-4), (I-a-5), (I-b-5), (I-c-5), (I-a-6), (I-b-6), or (I-c-6), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RC5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, q is 0, and r is 1. In certain embodiments of a compound of formula (I-a-4), (I-b-4), (I-c-4), (I-a-5), (I-b-5), (I-c-5), (I-a-6), (I-b-6), or (I-c-6), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, RC5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, q is 0, and r is 1. In certain embodiments of a compound of formula (I-a-4), (I-b-4), (I-c-4), (I-a-5), (I-b-5), (I-c-5), (I-a-6), (I-b-6), or (I-c-6), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is chloro, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, RX4is hydrogen or methyl, q is 0, and r is 1.
[0120] Also provided is a compound of formula (I-a-7) or (I-b-7):or a pharmaceutically acceptable salt thereof; wherein R1, RA1, RA3, RC1, RC5, Z1, Z2, and RX3are as defined above; RX5cis hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C1-C3 hydroxy thioalkoxy, or C1-C3 hydroxyalkylcarbonyl; each Rx5dis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-C3-alkyl; Z3and Z4are each independently selected from C, O, N, and S; s is 0, 1, 2, or 3; and t is 0, 1, or 2; provided at least one of Z3and Z4is C, and further provided that Z4is C when t is 0. It is to be understood that when Z3or Z4is C, that positionin the ring may be represented by -CH2-, -C(H)(RX5c)-, -C(H)(Rx5d)-, -C(Rx5d)2-, or -C(Rx5c)(Rx5d)-; and that when Z3or Z4is N, that position in the ring may be represented by -NH-, -N(RX5C)-, or -N(Rx5d)-; understanding that Rx5coccurs once and the number of Rx5dsubstitutions on the heterocyclyl are limited by the s variable.
[0121] Also provided is a compound of formula (I-a-8), (I-b-8), (I-a-9), (I-b-9), (I-a-10), or (I-b-10):or a pharmaceutically acceptable salt thereof; wherein R1, RA1, RA3, RC1, RC5, Z1, Z2, and RX3are as defined above; RX5cis hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C1-C3 hydroxy thioalkoxy, or C1-C3 hydroxyalkylcarbonyl; each Rx5dis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-C3-alkyl; s is 0, 1, 2, or 3; and t is 0, 1, or 2. In certain embodiments of a compound of formula (I-a-8), (I-b-8), (I-a-9), (I-b-9), (I-a-10), or (I-b-10), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferablycyclopropyl. In certain embodiments of a compound of formula (I-a-8), (I-b-8), (I-a-9), (I-b-9), (I-a-10), or (I-b-10), or a pharmaceutically acceptable salt thereof, s is 0 or 1. In certain embodiments of a compound of formula (I-a-8), (I-b-8), (I-a-9), (I-b-9), (I-a-10), or (I-b-10), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, and Z2is O. In certain embodiments of a compound of formula (I-a-8), (I-b-8), (I-a-9), (I-b-9), (I-a-10), or (I-b-10), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, Z2is O, and RX3is hydrogen. In certain embodiments of a compound of formula (I-a-8), (I-b-8), (I-a- 9), (I-b-9), (I-a-10), or (I-b-10), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, Z2is O, RX3is hydrogen, and s is 0 or 1. In certain embodiments of a compound of formula (I-a-8), (I-b-8), (I-a-9), (I-b-9), (I-a- 10), or (I-b-10), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RC5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, and s is 0 or 1. In certain embodiments of a compound of formula (I-a-8), (I-b-8), (I-a-9), (I-b-9), (I-a-10), or (I-b-10), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, RC:>is hydrogen, Z1is O, Z2is O, RX3is hydrogen, and s is 0 or 1. In certain embodiments of a compound of formula (I-a-8), (I-b-8), (I-a-9), (I-b-9), (I-a-10), or (I-b-10), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is chloro, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, and s is 0 or 1.
[0122] Also provided is a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13):or a pharmaceutically acceptable salt thereof; wherein R1, RA1, RA3, RC1, Rc5, Z1, Z2, and RXare as defined above; Rx5eis hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci- -hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl; each RX5fis independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-C3-alkyl; u, v, w, and x are each independently selected from 0, 1, and2, provided that u+v > 1; and y is 0, 1, 2, or 3. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, u is 0, v is 1, w is 1, and x is 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, u is 1, v is 1, w is 0, and x is 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, u is 2, v is 1, w is 0, and x is 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, y is 0 or 1, preferably 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, and Z2is O. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, Z2is O, and RX3is hydrogen. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Z1is O, Z2is O, RX3is hydrogen, and y is 0 or 1, preferably 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, and y is 0 or 1, preferably 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RC5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, u is 0, v is 1, w is 1, x is 0, and y is 0 or 1, preferably y is 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, u is 0, v is 1, w is 1, x is 0,and y is 0 or 1, preferably y is 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is chloro, Rcis hydrogen, Z1is O, Z2is O, RX3is hydrogen, u is 0, v is 1, w is 1, x is 0, and y is 0 or 1, preferably y is 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, R° is hydrogen, Z1is O, Z2is O, RX3is hydrogen, u is 1, v is 1, w is 0, x is 0, and y is 0 or 1, preferably y is 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, R° is hydrogen, Z1is O, Z2is O, RX3is hydrogen, u is 1, v is 1, w is 0, x is 0, and y is 0 or 1, preferably y is 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is chloro, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, u is 1, v is 1, w is 0, x is 0, and y is 0 or 1, preferably y is 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, u is 2, v is 1, w is 0, x is 0, and y is 0 or 1, preferably y is 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is fluoro, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, u is 2, v is 1, w is 0, x is 0, and y is 0 or 1, preferably y is 0. In certain embodiments of a compound of formula (I-a-11), (I-b-11), (I-a-12), (I-b-12), (I-a-13), or (I-b-13), or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RA1is fluoro, RA3is iodo, RC1is chloro, Rc5is hydrogen, Z1is O, Z2is O, RX3is hydrogen, u is 2, v is 1, w is 0, x is 0, and y is 0 or 1, preferably y is 0.
[0123] Also provided is a compound of a formula selected from:or a pharmaceutically acceptable salt thereof; wherein R1, RA1, RA3, RC1, RC5, Z1, Z2, RX3, RX4, RX5, Rx5a, Rx5b, RX5C, Rx5d, Rx5e, Rx5f, m, p, q r, s, t, u, v, w, x, y, and Ring D are as defined above. In certain embodiments of the foregoing formulae, or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl. In certain embodiments of the foregoing formulae, or a pharmaceutically acceptable salt thereof, R1is hydrogen, methyl, or cyclopropyl, preferably cyclopropyl, RX3is hydrogen, and RX4is hydrogen or methyl.
[0124] Also provided is a compound selected from:808283differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. A stereoisomer can be characterized by the absolute configuration of its asymmetric center(s) using the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomers or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.
[0126] Compounds of the present disclosure may be depicted flat without chiral information. These compounds can have multiple chiral centers and are contemplated to exist is various forms with various combinations of chiral centers. Additionally, these compounds can have various enantiomers, diastereomers, and atropisomers that can exist and are included herein.
[0127] Compounds of the present disclosure may be depicted as single stereoisomers.References to a single stereoisomer are meant to also include stereoisomeric mixtures including the named or depicted compound. Specific stereoisomers can be prepared by stereospecific synthesis using, for example, enantiomerically pure or enriched starting materials. Compounds of the present disclosure may have an isomeric purity greater than 90% enantiomeric excess. Compounds of the present disclosure may have an isomeric purity greater than 95% enantiomeric excess. Compounds of the present disclosure may have an isomeric purity greater than 98% enantiomeric excess. Compounds of the present disclosure may have an isomeric purity greater than 99% enantiomeric excess.
[0128] Compounds of the present disclosure may exhibit atropisomerism. Atropisomers are compounds that exist in different conformations arising from restricted rotation about a single bond. Atropisomers can be isolated as separate chemical species if the energy barrier to rotation about the single bond is sufficiently high that the rate of interconversion is slow enough to allow the individual rotomers to be separated from each other. Atropisomers canbe classified into three categories based on the amount of energy needed for the chiral axis to racemize via rotation and the length of time required for racemization to occur. Class 1 atropisomers possess barriers to rotation around the chiral axis of <84 kJ / mol (20 kcal / mol) and racemize over a time period measured in minutes or less at room temperature; Class 2 atropisomers possess a barrier to rotation between 84 and 117 kJ / mol (20-28 kcal / mol) and racemize over a time period measured in hours to months at room temperature; and Class 3 atropisomers possess a barrier to rotation >117 kJ / mol (28 kcal / mol) and racemize over a period of time measured in years at room temperature.
[0129] This present disclosure is intended to include all of the isomers, enantiomers, diastereomers, and atropisomers possible for the compounds disclosed herein or that could be made using the compounds disclosed herein. Individual isomers, enantiomers, diastereomers, and atropisomers may be separated or resolved at any convenient point in the synthesis of a compound of the present disclosure, by methods such as selective crystallization techniques or chiral chromatography (See for example, J. Jacques, et al., “Enantiomers, Racemates, and Resolutions", John Wiley and Sons, Inc., 1981, and E. L. Eliel and S. H. Wilen, “Stereochemistry' of Organic Compounds", Wiley-Interscience, 1994).
[0130] The designations “isomer 1” and “isomer 2” refer to the compounds that elute from chiral chromatography first and second, respectively, and if chiral chromatography is initiated early in the synthesis, the same designation is applied to subsequent intermediates and examples.
[0131] Compounds of the present disclosure may exist as pharmaceutically acceptable salts. Pharmaceutically acceptable salts, and common methodology for preparing them are well known in the art (see, e.g., P. Stahl, et al. Handbook of Pharmaceutical Salts: Properties, Selection, and Use, 1stRevised Edition (Wiley-VCH, 2011); S. M. Berge, et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, Vol. 66, No. 1, January 1977). Representative pharmaceutically acceptable salts include, e.g., water-soluble, and waterinsoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulanate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate,glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate, pantothenate, phosphate / diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts.
[0132] Compounds of the present disclosure may be isotopically-labeled. Examples of isotopes suitable for inclusion in a compound of the present disclosure include2H,3H,13C,14C,15N,18O,170,31P,32P,35S,18F, and36C1. Substitution with heavier isotopes such as deuterium, i.e.,2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Compounds of the present disclosure may incorporate positron-emitting isotopes for medical imaging and positron-emitting tomography (PET) studies for determining the distribution of receptors. Suitable positronemitting isotopes include11C,13N,15O. and18F. Isotope labeling can generally be affected by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using an appropriate isotopically-labeled reagent in place of non-isotopically -labeled reagent.
[0133] Compounds of the present disclosure may be prepared by a variety of procedures, some of which are illustrated in the Preparations and Examples below. The specific synthetic steps for each of the routes described may be combined in different ways, or in conjunction with steps from different routes, to prepare compounds or salts of the present invention. The products of each step in the Preparations below can be recovered by conventional methods, including extraction, evaporation, precipitation, chromatography, filtration, trituration, and crystallization.Therapeutic Uses
[0134] In another aspect, provided are therapies including a compound of formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of patients with a diseaseassociated with dysregulation of the MAPK / ERK pathway.
[0135] Also provided herein are therapies including a compound of formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of patients with a disease, such as cancer.
[0136] Also provided herein is a method of treating cancer, including administering to a patient in need thereof, a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the cancer is hematological cancer, lymphoma, myeloma, leukemia, neurological cancer, skin cancer, breast cancer, prostate cancer, colorectal cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, genitourinary cancer, bone cancer, renal cancer, or vascular cancer. In certain embodiments, the cancer is non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), uterine carcinoma, endometrial carcinoma, bladder cancer, esophageal cancer, thyroid cancer, melanoma, multiple myeloma, acute myeloid leukemia (AML), low-grade serous ovarian cancer, neurofibroma, or glioma.
[0137] Also provided herein is a method of treating cancer associated with dysregulation of the MAPK / ERK pathway, including administering to a patient in need thereof, a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. The status of the cancer as associated with dysregulation of the MAPK / ERK pathway can be determined by a number of assays known in the art. In certain embodiments, the cancer is hematological cancer, lymphoma, myeloma, leukemia, neurological cancer, skin cancer, breast cancer, prostate cancer, colorectal cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, genitourinary cancer, bone cancer, renal cancer, or vascular cancer. In certain embodiments, the cancer is non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), uterine carcinoma, endometrial carcinoma, bladder cancer, esophageal cancer, thyroid cancer, melanoma, multiple myeloma, acute myeloid leukemia (AML), low-grade serous ovarian cancer, neurofibroma, or glioma.
[0138] Also provided herein is a method of treating cancer, comprising administering to a patient in need thereof, a therapeutically effective amount of a compound according to formula (I), or a pharmaceutically acceptable salt thereof, in which the cancer has one ormore cells that overexpress MEK. The status of one or more cancer cells can be determined by a number of assays known in the art. In certain embodiments, the cancer is hematological cancer, lymphoma, myeloma, leukemia, neurological cancer, skin cancer, breast cancer, prostate cancer, colorectal cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, genitourinary cancer, bone cancer, renal cancer, or vascular cancer. In certain embodiments, the cancer is non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), uterine carcinoma, endometrial carcinoma, bladder cancer, esophageal cancer, thyroid cancer, melanoma, multiple myeloma, acute myeloid leukemia (AML), low-grade serous ovarian cancer, neurofibroma, or glioma.
[0139] Also provided herein is a method of treating cancer, comprising administering to a patient in need thereof, a therapeutically effective amount of a compound according to formula (I), or a pharmaceutically acceptable salt thereof, wherein the patient has a cancer that was determined to overexpress MEK. In certain embodiments, the cancer is hematological cancer, lymphoma, myeloma, leukemia, neurological cancer, skin cancer, breast cancer, prostate cancer, colorectal cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, genitourinary cancer, bone cancer, renal cancer, or vascular cancer. In certain embodiments, the cancer is non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), uterine carcinoma, endometrial carcinoma, bladder cancer, esophageal cancer, thyroid cancer, melanoma, multiple myeloma, acute myeloid leukemia (AML), low-grade serous ovarian cancer, neurofibroma, or glioma.
[0140] Further provided herein is a compound according to formula (I), or a pharmaceutically acceptable salt thereof, for use in therapy. In certain embodiments, the compound or a pharmaceutically acceptable salt thereof, is for use in treating cancer. The cancer can have one or more cancer cells that overexpress MEK. In certain embodiments, the cancer is hematological cancer, lymphoma, myeloma, leukemia, neurological cancer, skin cancer, breast cancer, prostate cancer, colorectal cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, genitourinary cancer, bone cancer, renal cancer, or vascular cancer. In certain embodiments, the cancer is non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), uterine carcinoma, endometrial carcinoma, bladder cancer, esophageal cancer, thyroid cancer, melanoma, multiple myeloma,acute myeloid leukemia (AML), low-grade serous ovarian cancer, neurofibroma, or glioma.
[0141] The compounds provided herein according to formula (I), or a pharmaceutically acceptable salt thereof, may also be used in the manufacture of a medicament for treating cancer. The cancer can have one or more cancer cells that overexpress MEK. In certain embodiments, the cancer is hematological cancer, lymphoma, myeloma, leukemia, neurological cancer, skin cancer, breast cancer, prostate cancer, colorectal cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, genitourinary cancer, bone cancer, renal cancer, or vascular cancer. In certain embodiments, the cancer is non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), uterine carcinoma, endometrial carcinoma, bladder cancer, esophageal cancer, thyroid cancer, melanoma, multiple myeloma, acute myeloid leukemia (AML), low-grade serous ovarian cancer, neurofibroma, or glioma.
[0142] Also provided herein are methods of diagnosing cancer associated with dysregulation of the MAPK / ERK pathway, including administering to a patient in need thereof, a diagnostically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
[0143] Also provided herein are methods of imaging cancer associated with dysregulation of the MAPK / ERK pathway, including administering to a patient in need thereof, an imaging effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.Pharmaceutical Compositions
[0144] In another aspect, provided herein are pharmaceutical compositions including a compound of formula (I), or a pharmaceutically acceptable salt thereof. A compound of formula (I), or a pharmaceutically acceptable salt thereof, can be formulated for oral administration in forms such as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions. A compound of formula (I), or a pharmaceutically acceptable salt thereof, can also be formulated for intravenous (bolus or in-fusion), intraperitoneal, topical, subcutaneous, intramuscular or transdermal (e.g., patch) administration, all using forms well known to those of ordinary skill in the pharmaceutical arts.
[0145] A compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, may be administered to a subject by any convenient route of administration, whether systemically / peripherally or topically (i.e., at the site of desired action).
[0146] Routes of administration include, but are not limited to, oral (e.g. by ingestion); buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, for example, by injection, including subcutaneous, intrademal, intramuscular, intravenous, intra-arterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot or reservoir, for example, subcutaneously or intramuscularly.
[0147] In a preferred embodiment, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is administered by injection.
[0148] In another preferred embodiment, a compound of formula (I), or a pharmaceutically acceptable salt thereof, serves as a payload of an antibody drug conjugate (ADC). Such ADCs are typically administered by injection, particularly subcutaneous injection.
[0149] A pharmaceutical composition containing a compound of formula (I), or a pharmaceutically acceptable salt thereof, may be prepared using pharmaceutically acceptable carriers, diluents, or excipients that are compatible with the other additives of the composition or formulation and not deleterious to the patient. Examples of pharmaceutical compositions and processes for their preparation can be found in “Remington: The Science and Practice of Pharmacy”, Loyd, V., et al. Eds., 22nd Ed., Mack Publishing Co., 2012. Nonlimiting examples of pharmaceutically acceptable carriers, diluents, and excipients include the following: saline, water, starch, sugars, mannitol, and silica derivatives; binding agents such as carboxymethyl cellulose, alginates, gelatin, and polyvinyl-pyrrolidone; kaolin and bentonite; and polyethyl glycols.Definitions
[0150] The term “alkoxy” refers to an alkyl group which contains a terminal oxygen in the chain, i.e., -O(alkyl). Exemplary alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, t-butoxy, and pentoxy.
[0151] The term “alkoxy alkyl” refers to an alkyl group substituted with an alkoxy group. Exemplary alkoxyalkyl groups include, but are not limited to, -CH2CH2OCH3, and -C(H)(OCH3)CH3.
[0152] The term “alkyl” refers to a saturated straight- or branched-chain hydrocarbon group, preferably containing 1-12 carbon atoms, more preferably 1-6 carbon atoms or 1-3 carbon atoms. Examples of a Ci-Ce alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.
[0153] The term “alkylamino” refers to an amino group substituted with one alkyl group (i.e., -NH(alkyl)).
[0154] The term “alkylcarbonyl” refers to an alkyl group which contains a terminal carbonyl in the chain, i.e., -C(O)-(alkyl).
[0155] The term “alkylsulfonyl” refers to an alkyl group which contains a terminal sulfonyl in the chain, i.e., -S(O)2-(alkyl).
[0156] The term “amino” refers to -NH2.
[0157] The term “aminoalkyl” refers to an alkyl group substituted with an amino group on one of the alkyl group carbons.
[0158] The term “aryl” unless otherwise specifically defined refers to a cyclic, aromatic hydrocarbon group that has 1 to 3 aromatic rings. An aryl may have one or more saturated, or partially unsaturated rings (e.g., fused with a fully unsaturated aromatic ring). Exemplary aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthalenyl, and tetrahydrobenzoannulenyl. The term “C6-C10aryl” refers to an aryl, as defined herein, that is monocyclic or bicyclic and contains 6 to 10 carbons.
[0159] The term “arylalkyl” refers to an alkyl group substituted with an aryl group on one of the alkyl group carbons. Exemplary arylalkyl groups include, but are not limited to, benzyl,2-phenylethyl, 3 -phenylpropyl, and 2-naphth-2-ylethyl.
[0160] The term "cycloalkyl" unless otherwise specifically defined refers to a cyclic saturated hydrocarbon group having 3 to 20 ring carbons, preferably 3 to 16 ring carbons, and more preferably 3 to 12 ring carbons or 3 to 10 ring carbons or 3 to 6 ring carbons or 3 to 5 ring carbons or 4 to 6 ring carbons. A cycloalkyl may include multiple, preferably 1 or 2, fused, bridged, or spirocyclic rings. Exemplary monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Exemplary fused cycloalkyls include, but are not limited to, bicyclo[1.1.0]butane, bicyclo[2.1.0]pentane, bicyclo[3.1.0]hexane, bicyclo[3.2.0]heptane, bicyclo[4.1.0]heptane, and bicyclo[4.2.0]octane. Exemplary bridged cycloalkyls include, but are not limited to, bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, bicyclo[3.2.1]octane, and bicyclo[2.2.2]octane. Exemplary spirocyclic cycloalkyls include, but are not limited to, spiro[2.2]pentane, spiro[2.5]octane, spiro[3.5]nonane, spiro[3.5]nonane, spiro[3.5]nonane, spiro[4.4]nonane, spiro[2.6]nonane, spiro[4.5]decane, spiro [3.6] decane, and spiro[5.5]undecane. The term “C3-C5 cycloalkyl” refers to a cycloalkyl, as defined herein, that is monocyclic and contains from 3 to 5 carbons. The term “C4-C6 cycloalkyl” refers to a cycloalkyl, as defined herein, that is monocyclic and contains from 4 to 6 carbons. The term “C3-C10 cycloalkyl” refers to a cycloalkyl, as defined herein, that is monocyclic or bicyclic (e.g., fused, bridged, or spiro-linked bicyclic cycloalkyl) and contains from 3 to 10 carbons. The term “C6-C10cycloalkyl” refers to a cycloalkyl, as defined herein, that is monocyclic or bicyclic (e.g., fused, bridged, or spiro-linked bicyclic cycloalkyl) and contains from 6 to 10 carbons.
[0161] The term “cycloalkylalkyl” refers to an alkyl group substituted with a cycloalkyl group on one of the alkyl group carbons. Exemplary cycloalkylalkyl groups include, but are not limited to, cyclopropylmethyl, 2-cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, and 4-cycloheptylbutyl.
[0162] The term “dialkylamino” refers to an amino group substituted with two alkyl groups (i.e., -N(alkyl)2).
[0163] The term “haloalkoxy” refers to an alkoxy group which is substituted with one or more halogen, preferably 1, 2, or 3 halogen. Exemplary haloalkoxy groups include, but arenot limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, and trichloromethoxy.
[0164] The term “haloalkyl" refers to an alkyl group which is substituted with one or more halogen, preferably 1, 2, or 3 halogen. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, and trichloromethyl.
[0165] The term “halogen” refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I).
[0166] The term “halothioalkoxy” refers to a thioalkoxy group which is substituted with one or more halogen, preferably 1, 2, or 3 halogen.
[0167] The term “heteroaryl” unless otherwise specifically defined refers to a monocyclic or polycyclic (e.g., bicyclic, tricyclic, or tetracyclic) aromatic group of 5 to 24 ring atoms, preferably 5 to 10 ring atoms, containing one or more ring heteroatoms selected from N, O, S, P, or B, preferably 1, 2, 3, or 4 ring heteroatoms selected from N, O, or S, the remaining ring atoms being carbon. Examples of heteroaryl groups include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[l,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[l,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuranyl, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazinyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][l,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazolo[l,5-a]pyridinyl, [l,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[l,2-a]pyrimidinyl, tetrahydro pyrrolo[l,2-a]pyrimidinyl, 3,4-dihydro-2H-l-pyrrolo[2,l-b]pyrimidine, dibenzo[b,d]thiophene, pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, lH-pyrido[3,4-b][l,4]thiazinyl, benzooxazolyl, benzoisoxazolyl, furo [2, 3-b]pyridinyl, benzothiophenyl, 1,5-naphthyridinyl, furo[3,2-b]pyridine, [l,2,4]triazolo[l,5-a]pyridinyl, benzo[l,2,3]triazolyl, imidazo[l,2-a]pyrimidinyl, [l,2,4]triazolo[4,3-b]pyridazinyl, benzo[c][l,2,5]thiadiazolyl, benzo[c][l,2,5]oxadiazole, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo[l,5-b][l,2]oxazinyl, 4, 5,6,7-tetrahydropyrazolo[l,5-a]pyridinyl, thiazolo[5,4-d]thiazolyl, imidazo[2,l-b|| 1,3,4|thiadiazolyl. thieno[2,3-b]pyrrolyl, and 3H-indolyl. Heteroaryl groups may have one or more saturated or partially unsaturated rings fused with one or more fully unsaturated aromatic rings; the saturated or partially unsaturated rings are optionally substituted with one or more oxo, preferably 1 or 2 oxo. Exemplary ring systems of these heteroaryl groups include, but are not limited to, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-lH-isoquinolinyl, 2, 3 -dihydrobenzofuranyl, benzofuranonyl, oxindolyl, indolyl, l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-onyl, 7,8-dihydro-6H-pyrido[3,2-b]pyrrolizinyl, 8H-pyrido[3,2-b]pyrrolizinyl, 1,5,6,7-tetrahydrocyclopenta[b]pyrazolo[4,3-e]pyridinyl, 7,8-dihydro-6H-pyrido[3,2-b]pyrrolizinyl, pyrazolo[l,5-a]pyrimidin-7(4H)-onyl, 3,4-dihydropyrazino[l,2-a]indol-l(2H)-onyl, benzo[c][l,2]oxaborol-l(377)-olyl, 6, 6a, 7,8-tetrahydro-9H-pyrido[2,3-&]pyrrolo[ l,2- ][ 1,4]oxazin-9-onyl, and 6a’,7’-dihydro-6’H,9’H-spiro[cyclopropane-l,8’-pyrido[2,3-Z?]pyrrolo[l,2-6Z][l,4]oxazin]-9’-onyl. The term “5- to 10-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S” refers to a heteroaryl, as defined herein, that is monocyclic or fused bicyclic and contains 5 to 10 ring atoms, wherein 1, 2, or 3 of the ring atoms are heteroatoms, each independently selected from N, O, and S. The term “5- to 10-membered heteroaryl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S” refers to a heteroaryl, as defined herein, that is monocyclic or fused bicyclic and contains 5 to 10 ring atoms, wherein 1, 2, 3, or 4 of the ring atoms are heteroatoms, each independently selected from N, O, and S.
[0168] The term “5-membered heteroaryl” unless otherwise specifically defined refers to a monocyclic aromatic group of 5 ring atoms, containing one or more ring heteroatoms selected from N, O, S, P, or B, preferably 1, 2, 3, or 4 ring heteroatoms selected from N, O, or S, the remaining ring atoms being carbon atoms. Exemplary 5-membered heteroaryl groups include, but are not limited to, furyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, thiadiazole, triazolyl and tetrazolyl.
[0169] The term “6-membered heteroaryl’’ unless otherwise specifically defined refers to a monocyclic aromatic group of 6 ring atoms, containing one or more ring heteroatoms selectedfrom N, O, S, P, or B, preferably 1, 2, 3, or 4 ring heteroatoms selected from N, O, or S, the remaining ring atoms being carbon atoms. Exemplary 6-membered heteroaryl groups include, but are not limited to, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl.
[0170] The term “heteroarylalkyl” refers to an alkyl group substituted with a heteroaryl group on one of the alkyl group carbons. Exemplary heteroarylalkyl groups include, but are not limited to, fur-3 -ylmethyl, lH-imidazol-2-ylmethyl, lH-imidazol-4-ylmethyl, 1 -(pyridine-4-y l)ethy 1, pyridin-3-ylmethyl, pyrimidin-5-ylmethyl, 2-(pyrimidin-2-yl)propyl, thien-2-ylmethyl, and thien-3-ylmethyl.
[0171] The term "heterocyclyl" unless otherwise specifically defined refers to a monocyclic or polycyclic (e.g., bicyclic, tricyclic, or tetracyclic) saturated or partially unsaturated ring system with 3-16 ring atoms (e.g., 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic or tetracyclic ring system) having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic or tetracyclic, said heteroatoms selected from N, O, S, P, or B, preferably selected from N, O, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic or tetracyclic, respectively). One or more ring atoms, preferably 1-2 ring atoms, of a heterocyclyl may be substituted with oxo (forming, e.g., a lactam), thiooxo, or imino, valence permitting. One or more N or S ring atoms, preferably 1 or 2, may be substituted by 1-2 oxido (forming, e.g., an N-oxide, an S-oxide, or an S, S-dioxide), valence permitting. Exemplary heterocyclyl groups include, but are not limited to, piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, tetrahydropyridyl, dihydropyrazinyl, dihydropyridyl, dihydropyrrolyl, dihydrofuranyl, and dihydrothiophenyl. A heterocyclyl may include multiple, preferably 1 or 2, fused, bridged, or spirocyclic rings. Exemplary fused heterocyclyls include, but are not limited to, 2-azabicyclo[1.1.0]butane, 2-azabicyclo[2.1.0]pentane, 3-azabicyclo[3.1.0]hexane, 3-azabicyclo[3.2.0]heptane, octahydrocyclopenta[c]pyrrole, 3-azabicyclo[4.1.0]heptane, 7-azabicyclo[4.2.0]octane, 2-oxabicyclo[1.1.0]butane, 2-oxabicyclo[2.1.0]pentane, 3-oxabicyclo[3.1.0]hexane, 3-oxabicyclo[3.2.0]heptane, 3-oxabicyclo[4.1.0]heptane, and 7-oxabicyclo[4.2.0]octane. Exemplary bridged heterocyclyls include, but are not limited to, 2-azabicyclo[l.l.l]pentane, 5-azabicyclo[2.1.1]hexane, 7-azabicyclo[2.2.1]heptane, 6-azabicyclo[3.1.1]heptane, 2-azabicyclo[2.2.2]octane, 3 -azabi cyclo [3.2. l]octane, 2-oxabicyclo[l.l.l]pentane, 5-oxabicyclo[2.1.1]hexane, 7-oxabicyclo[2.2.1]heptane, 6-oxabicyclo[3.1.1]heptane, 2-oxabicyclo[2.2.2]octane, and 3-oxabicyclo[3.2.1]octane.Exemplary spirocyclic heterocyclyls include, but are not limited to, 2-azaspiro[2.2]pentane, 4-azaspiro[2.5]octane, l-azaspiro[3.5]nonane, 2-azaspiro[3.5]nonane, 7-azaspiro[3.5]nonane, 2-azaspiro[4.4]nonane, 6-azaspiro[2.6]nonane, l,7-diazaspiro[4.5]decane, 7-azaspiro[4.5]decane 2,5-diazaspiro[3.6]decane, 3-azaspiro[5.5]undecane, 2-oxaspiro[2.2]pentane, 4-oxaspiro[2.5]octane, l-oxaspiro[3.5]nonane, 2-oxaspiro[3.5]nonane, 7-oxaspiro[3.5]nonane, 2-oxaspiro[4.4]nonane, 6-oxaspiro[2.6]nonane, 1,7-dioxaspiro[4.5]decane, 2,5-dioxaspiro[3.6]decane, 1 -oxaspiro [5.5]undecane, 3-oxaspiro[5.5]undecane, and 3-oxa-9-azaspiro[5.5]undecane. The term “3- to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S” refers to a heterocyclyl, as defined herein, that is monocyclic or bicyclic (e.g., fused, bridged, or spiro-linked bicyclic heterocyclyl) and contains 3 to 10 ring atoms, wherein 1, 2, 3, or 4 of the ring atoms are heteroatoms, each independently selected from N, O, and S. The term “5- to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S” refers to a heterocyclyl, as defined herein, that is monocyclic or bicyclic (e.g., fused, bridged, or spiro-linked bicyclic heterocyclyl) and contains 5 to 10 ring atoms, wherein 1, 2, 3, or 4 of the ring atoms are heteroatoms, each independently selected from N, O, and S. The term “Rx4 and Rxs together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S” refers to a heterocyclyl, as defined herein, that is monocyclic or bicyclic (e.g., fused, bridged, or spiro-linked bicyclic heterocyclyl) and contains 4 to 10 ring atoms, wherein the heterocyclyl contains a nitrogen heteroatom through which RX4and Rx5are bonded, and optionally contains 1, 2, or 3 further ring heteroatoms, each independently selected from N, O, and S.
[0172] The term “heterocyclylalkyl” refers to an alkyl group substituted with a heterocyclyl group on one of the alkyl group carbons. Exemplary heterocyclylalkyl groups include, but are not limited to, piperidin-4-ylmethyl and piperazin- 1-ylmethyl.
[0173] The term “hydroxy alkoxy” refers to an alkoxy group substituted with a hydroxy group on one of the alkoxy group carbon atoms.
[0174] The term “hydroxyalkoxyalkyl” refers to an alkyl group substituted with a hydroxyalkoxy group on one of the alkyl group carbons.
[0175] The term “hydroxyalkyl” refers to an alkyl group which is substituted with a hydroxy group on one of the alkyl group carbons. Exemplary hydroxyalkyl groups include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, and 3 -hydroxypropyl.
[0176] The term “hydroxy thioalkoxy” refers to a thioalkoxy group which is substituted with a hydroxy group on one of the thioalkoxy group carbon atoms.
[0177] The term “hydroxyalkylcarbonyl” refers to an alkylcarbonyl group which is substituted with a hydroxy group on one of the alkyl group carbon atoms of the alkylcarbonyl.
[0178] The term “imino” refers to =NH or =N-Ci-Cs alkyl.
[0179] The term “optionally substituted” refers to a group that is unsubstituted or substituted with one or more of the referenced substituent(s).
[0180] The term “oxo” refers to a divalent doubly bonded oxygen atom, i.e., =0.
[0181] The term “thiol” refers to -SH.
[0182] The term “thioalkoxy” or “alkylthio” refers to an alkyl group which contains a terminal sulfur in the chain, i.e., -S(alkyl). Exemplary thioalkoxy groups include, but are not limited to, thiomethoxy (i.e., -SCH3) and thioethoxy (i.e., -SCH2CH3).
[0183] The term “thiooxo” refers to a divalent doubly bonded sulfur atom, i.e., =S.
[0184] It is understood that for example the terms “alkoxy”, “alkyl”, “haloalkyl”, “haloalkoxy” and “cycloalkyl” can be further defined by the numbers of carbons they contain, such as for example the term “Ci-Ce alkoxy” refers to an alkoxy group containing 1-6 carbon atoms.
[0185] The terms “cancer” or “cancerous” refers to or describes the physiological condition in patients that is typically characterized by unregulated cell proliferation. Included in this definition are benign and malignant cancers.
[0186] The term “patient”, or “subject” is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon, or rhesus. Preferably, the mammal is human.
[0187] The term “therapeutically effective amount” when used in connection with acompound refers to the amount or dose of the compound which upon single or multiple dose administration to the patient provides the desired effect in the patient under treatment. In determining the therapeutically effective amount for a patient, a number of factors may be considered, including, but not limited to: the species of patient; its size, age, and general health; the specific disease or disorder involved; the degree of or involvement or the severity of the disease or disorder; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
[0188] The term “treating” with regard to a subject, includes restraining, slowing, stopping, or reversing the progression or severity of an existing symptom or disease. Treating can include specifically slowing the growth of a cancerous lesion or progression of abnormal cell growth and / or cell division.Examples
[0189] The following examples are provided for illustration purposes only. The abbreviations used herein are defined according to Aldrichimica Acta, vol. 17, No. 1, 1984. Other abbreviations are defined as follows: “ACN” refers to acetonitrile; “AcOH” refers to acetic acid; “BOC2O” refers to di-tert-butyl dicarbonate; “DABCO” refers to 1,4-diazabicyclo[2.2.2]octane; “DBU” refers to l,8-diazabicyclo[5.4.0]undec-7-ene; “DCE” refers to 1,2-dichloroethane; “DCM” refers to dichloromethane; “DIAD” refers to diisopropyl azodicarboxylate; “DMA” refers to N, N-dimethylacetamide; “DMAP” refers to 4-dimethylaminopyridine; “DMF” refers to dimethylformamide; “DMSO” refers to dimethyl sulfoxide; “DSC” refers to N,N'-disuccinimidyl carbonate; “EDC” refers to 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; “EtOAc” refers to ethyl acetate; “EtOH” refers to ethanol; “EnSiH” refers to triethylsilane; “FA” refers to formic acid; “h” refers to hour(s); “HPLC” refers to high performance liquid chromatography; “HOBt” refers to 1-hydroxybenzotriazole; “IP A” refers to isopropanol; “LC-MS” refers to liquid chromatography mass spectrometry; “LiHMDS” refers to lithium bis(trimethylsilyl)amide; “MeOH” refers to methanol; “min” refers to minute(s); “MTBE” refers to methyl tert-butylether; “NCS” refers to N-chlorosuccinimide “NMR” refers to nuclear magnetic resonance; “PE” refers to petroleum ether; “PPI13” refers to triphenylphosphine; “prep-HPLC” refers to preparatory high performance liquid chromatography; “prep-UPLC” refers to preparatory ultra performance liquid chromatography; “PG” refers to protecting group; “PyBOP” refers to benzotriazole-l-yl-oxy-trA-pyrrolidino-phosphonium hexafluorophosphate; “RT” refers to room temperature; “TBAF” refers to tetra-n-butylammonium fluoride; “TBS” refers to tert-butyl(dimethyl)silyl; “TEA” refers to triethylamine; “TFA” refers to trifluoroacetic acid; “Tf2O” refers to trifluoromethanesulfonic anhydride; “THF” refers to tetrahydrofuran.PREPARATIONSPreparation 1tert-Butyl (cis-2-((tetrahydro-2H-pyran-2-yl)oxy)cyclobutyl)carbamate|0190| To a stirred mixture of tert-butyl N-|cis-2-hydroxycyclobutyl|carbamate (1.1 g, 5.875 mmol) and 4-methylbenzene-1-sulfonate pyridin-1-ium (295.27 mg, 1.175 mmol) in DCM (10 mF) was added 3,4-dihydro-2H-pyran (741.27 mg, 8.813 mmol) dropwise at 0 °C under N2. The resulting mixture was stirred at RT overnight. The mixture was diluted with DCM (80 mF), washed with H2O (3 x 80 mF), saturated aq. NaCl solution (80 mF), and dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated to afford the title compound (1.66 g) as a light-yellow oil. LC / MS (m / z): 272 [M+H].Preparation 2cis-N-Methyl-2-((tetrahydro-2H-pyran-2-yl)oxy)cyclobutan-l-amine
[0191] To a stirred solution of tert-butyl N-[cis-2-(oxan-2-yloxy)cyclobutyl]carbamate (1.64 g, 6.044 mmol) in THF (25 mF) was added Li AIH4 (9.07 mF, 18.132 mmol, 2M in THF)dropwise at -20 °C under N2. The mixture was stirred at 60 °C overnight. The reaction was quenched with ice H2O at -30 °C. The mixture was filtered, and the filter cake was washed with THF (3 x 10 mL). The filtrate was concentrated to afford a residue. The residue was purified by silica gel flash chromatography (5% MeOH in DCM) to afford the title compound (600 mg, 54%) as a light-yellow oil. LC / MS (m / z): 186 [M+H],Preparation 3( lR,2S)-2-((tert-Butyldimethylsilyl)oxy)cyclopentan-l -amine
[0192] To a solution of (lS,2R)-2-aminocyclopentan-l-ol HC1 (500 mg, 3.63 mmol) in DCM (15 mL) were added DBU (830 mg, 5.45 mmol) and tert-butyldimethylchlorosilane (657 mg, 4.36 mmol), followed by DMAP (44.4 mg, 363 pmol). The reaction was stirred at RT for 1 h. The reaction was diluted with DCM and washed with saturated aq. NH4CI solution. The aq. layer was extracted with DCM (3x). The organic layers were dried over MgSCU, filtered and concentrated to afford the title compound (780 mg, 100%).Preparation 45-Azaspiro[2.5]octan-8-ol HC1
[0193] A solution of tert-butyl 8-hydroxy-5-azaspiro[2.5]octane-5-carboxylate (700 mg, 3.08 mmol) in HC1 in 1,4-dioxane (4M, 20 mL) was stirred at RT for 2 h under N2. The resulting mixture was concentrated under reduced pressure to afford the title compound (560 mg).LC / MS (m / z): 128 [M+H],
[0194] The compound in the following table was prepared essentially as described in Preparation 4 using the appropriate protected amine.Preparation 64-Amino-3-chloro-N-(2-hydroxyethyl)benzenesulfonamide
[0015] A mixture of 4-amino-N-(2-hydroxyethyl)benzenesulfonamide (288 mg, 1.33 mmol) and NCS (196 mg, 1.47 mmol) in AcOH (5 mL) was stirred at 50 °C overnight. The resulting mixture was diluted with EtOAc (100 mL) and neutralized to pH = 7 with saturated aq. NaHCCL solution. The resulting mixture was washed with H2O (2 x 60 mL) and dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated. The residue was purified by silica gel flash chromatography (25% EtOAc in PE) to afford the title compound (234 mg, 70%) as a white solid. LC / MS (m / z): 251 [M+H],Preparation 73-Cyclopropyl-l-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo-l,2,3,4,7,8- hexahydropyrido[2,3-c / ]pyrimidin-5-yl trifluoromethanesulfonate
[0196] A solution of 3-cyclopropyl-l-(2-fluoro-4-iodophenyl)-5-hydroxy-6,8-dimethylpyrido[2,3-r / ]pyrimidine-2,4,7(lH,3H,8H)-trione (40.00 g, 82.77 mmol) and 2,6-lutidine ( 11.80 g, 110 mmol) in CHCI3 (200 mL) under N2 was cooled to 0 °C for 25 min, and Tf2< D (29.19 g, 104 mmol) was added dropwise over 10 min. The mixture was stirred at 0 °C for 1 h, and at RT for 1.25 h. The reaction was diluted with CHCI3 (200 mL), and washed successively with saturated aq. NaHCCL solution (2 x 250 mL), IN aq. HC1 (300 mL), saturated aq. NaCl solution, and concentrated. The residue was dissolved in IPA (600 mL), sonicated, heated to reflux, and cooled to RT. The obtained slurry was filtered. The precipitate was triturated in IPA (600 mL), filtered, and the solids were dried to afford the title compound (46.28 g, 86%) as a white solid. LC / MS (m / z): 616 [M+H],Preparation 85-((3-Amino-2-fhiorophenyl)amino)-3-cyclopropyl-l-(2-fluoro-4-iodophenyl)-6,8- dimethylpyrido[2,3-6 / ]pyrimidine-2,4,7(lH,3H,8H)-trione
[0197] To a solution of 3-cyclopropyl-l-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxo-l,2,3,4,7,8-hexahydropyrido[2,3-d]pyrimidin-5-yl trifluoromethanesulfonate (5186 mg, 8.007 mmol) in DMA (50 mL) were added 2,6-lutidine (3.52 g, 32.8 mmol) and 2 -fluorobenzene -1,3-diamine (2.563 g, 20.32 mmol). The reaction vessel was sealed, and the mixture was stirred at 130 °C for 15 h. The reaction was diluted with H2O (300 mL). The resultant precipitate was filtered, rinsed with H2O, and dried to afford the title compound (4.95 g, 96%) as a gray solid. LC / MS (m / z): 592 [M+H],
[0198] The compounds in the following table were prepared essentially as described in Preparation 8 using the appropriate amine.Preparation 12l-(3-Amino-2-fluorophenyl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8- dimethylpyrido[4,3-<f|pyrimidine-2,4,7(lH,3H,6H)-trione
[0199] To a solution of 5-((3-amino-2-fluorophenyl)amino)-3-cyclopropyl-l-(2-fluoro-4-iodophenyl)-6,8-dimethylpyrido[2,3- ]pyrimidine-2,4,7(lH,3H,8H)-trione (5.5 g, 9.3 mmol) in THF (20 mL) was slowly added a solution of NaOCIT? in MeOH (0.60 g, 2.1 mL, 5.4M, 11 mmol). The mixture was stirred at RT for 6 h. The reaction was concentrated, and the residue was quenched with saturated aq. NH4CI solution. The solids were filtered off, washed with H2O followed by a small amount of MeOH and dried to afford the title product (4.5 g, 82 %). LC / MS (m / z): 592 [M+H],
[0200] The compounds in the following table were prepared essentially as described in Preparation 12.Preparation 15l-(3-Amino-2-fluorophenyl)-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3- c?]pyrimidine-2, 4,7(1 H,3H,6H)-trione
[0201] To a solution of l-(3-amino-2-fluorophenyl)-5-((2-fluoro-4-iodophenyl)amino)-3-(4-methoxybenzyl)-6,8-dimethylpyrido[4,3-c?]pyrimidine-2,4,7(lH,3H,6H)-trione (4090 mg, 5.79 mmol) in anisole (50 mL) was added AlCh (11.57 g, 86.80 mmol) at 0 °C. The mixturewas stirred at RT overnight. The reaction was cooled to 0 °C, and recharged with AICI3 (3.86 g, 28.93 mmol). The mixture was warmed to RT, and stirred for 5 h. The reaction was cooled to 0 °C, then slowly quenched with MeOH. The solution was concentrated, then diluted with EtOAc (250 mL) and H2O (150 mL). The aq. layer was extracted with EtOAc (2 x 100 mL), and the combined organic layers were washed with saturated aq. NaCl solution, dried over NaSO4, filtered, and concentrated. The residue was triturated in DCM / heptanes (2:8) to afford the title compound (2.80 g, 83%) as a light beige solid. LC / MS (m / z): 552 [M+H],Preparation 16l-(3-Amino-2-fluorophenyl)-5-((2-fluoro-4-iodophenyl)amino)-3,6,8-trimethylpyrido[4,3- d]pyrimidine-2,4,7(lH,3H,6H)-trione
[0202] To a solution of l-(3-amino-2-fluorophenyl)-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(lH,3H,6H)-trione (297 mg, 0.54 mmol), MeOH (43 mg, 1.35 mmol), and PPI13 (283 mg, 1.08 mmol) in THF (10 mL) was added dropwise DIAD (218 mg, 1.08 mmol). The mixture was stirred at RT for 2.25 hours then concentrated in vacuo. The residue was loaded on a silica and purified by flash silica gel chromatography (0% to 100% EtOAc in heptanes) to afford the title compound (118 mg, 40% purity) LC / MS (m / z): 566 [M+H]+. Material was taken on to next step as is.Preparation 17l-(3-Amino-2-fluorophenyl)-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-((2-fluoro-4- iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(lH,3H,6H)-trione10203 J To a solution of l-(3-amino-2-fluorophenyl)-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(lH,3H,6H)-trione (127 mg, 0.22 mmol), 2-((tert-butyldimethylsilyl)oxy)ethan-l-ol (62 mg, 0.35 mmol), and PPhs (115 mg, 0.49 mmol) in anhydrous THF (4.0 mL) was added dropwise DIAD (89 mg, 0.44 mmol). The mixture was stirred at RT for 25 minutes then concentrated. The residue was purified by flash silica gel chromatography (0% to 100% EtOAc in heptanes). Fractions a7-9 were combined and concentrated in vacuo to the title compound (233 mg, 90 %, 60% Purity) as a colorless oil. LC / MS (m / z): 710 [M+H],Preparation 182-((tert-Butyldimethylsilyl)oxy)ethyl -l-[2-fluoro-3-({methyl[2- methoxyethyl]sulfamoyl}amino)phenyl]-5-[(2-fluoro-4-iodophenyl)amino]-6,8- dimethylpyrid()|4.3-i / |pyrimidine-2.4.7-tnone
[0204] To a solution of l-(3-amino-2-fluorophenyl)-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-((2-fluoro-4-iodophenyl)amino)-6,8- dimethylpyrido[4,3-d]pyrimidine-2,4,7(lH,3H,6H)-trione (117 mg, 60% wt, 0.10 mmol) in DCM (2.0 mL) and DMF (0.5 mL) was added 1-(fluorosulfonyl)-2,3-dimethyl-lH-imidazol-3-ium trifluoromethanesulfonate (129 mg, 0.39 mmol) and triethylenediamine (66 mg, 0.59 mmol). The mixture was stirred at RT for 30 minutes then calcium di|bis(trifluoromethanesulfonyl)imide| (118 mg, 0.20 pmol), and 2-methoxy-N-methylethan-1 -amine (26 mg, 0.30 mmol) were added. The mixture was stirred at RT for 45 minutes then loaded directly onto a silica cartridge. The column was eluted with 0% to 100% EtOAc in heptanes. The appropriate fractions were concentrated to afford the title compound (80 mg, 90 %, 95% purity) as white solid. LC / MS (m / z): 861 [M+H],
[0205] The compounds in the following table were prepared essentially as described in Preparation 18.Preparation 213-(N-(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido[4,3-i / ]pyrimidin-l(2H)-yl)-2-fluorophenyl)sulfamoyl)propyl acetate
[0206] To a solution of l-(3-amino-2-fluorophenyl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(lH,3H,6H)-trione (100 mg, 152 pmol) in pyridine (1 mL) was added 3-(chlorosulfonyl)propyl acetate (45.8 mg, 228 pmol) followed by DMAP (22.3 mg, 183 pmol). The mixture was stirred at RT overnight. The reaction was recharged with additional 3-(chlorosulfonyl)propyl acetate (39.7mg, 198 pmol), and stirred for 1 h. The reaction was quenched by the addition of HC1 (IN aq., 10 mL), and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with saturated aq. NaHCCh (10 mL), saturated aq. NaCl solution, dried over NaSO4, filtered, and concentrated. The residue was purified by silica gel flash chromatography (0 to 50% EtOAc / EtOH (3:l / v:v) in heptanes). The appropriate fractions were concentrated to afford the title compound (56 mg, 29%) as a white solid. LC / MS (m / z): 756 [M+H],Preparation 223-Cyclopropyl-l-[2-fluoro-3-({[((n?rt- butyldimethylsilyl)oxy)ethyl]sulfamoyl]amino)phenyl]-5-[(2-fluoro-4-iodophenyl)amino]- 6, 8-dimethylpyrido[4,3-i ]pyriniidine-2, 4, 7-trione
[0207] To a solution of l-(3-amino-2-fluorophenyl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-6 / ]pyrimidine-2,4,7(lH,3H,6H)-trione (95.0 mg, 145 pmol) in DCM (2 mL) and DMF (0.5 mL) was added l-(fluorosulfonyl)-2,3-dimethyl-lH-imidazol-3-ium trifluoromethanesulfonate (190 mg, 578 pmol) at RT. The mixture was stirred at RT for 3 h. To a solution of 2-((tert-butyldimethylsilyl)oxy)ethan-l -amine (101 mg, 578 pmol) in DCM (1 mL) was added TEA (73.2 mg, 723 pmol). The first solution was added dropwise to the second solution, and the mixture stirred at RT overnight. The reaction was concentrated, and the residue was purified by silica gel flash chromatography (0 to 100% EtOAc in heptanes). The appropriate fractions were concentrated to afford the title compound (34 mg, 29%) as a white solid. LC / MS (m / z): 829 [M+H],
[0208] The compounds in the following table were prepared essentially as described in Preparation 22.Preparation 27(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido[4,3-6Z]pyrimidin-l(2H)-yl)-2-fluorophenyl)sulfamoyl fluoride
[0209] To a suspension of l-(3-amino-2-fluorophenyl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-6Z]pyrimidine-2,4,7(lH.3H,6H)-trione (600 mg, 862 pmol) in DCM (10 mL) and DMF (2.5 mL) was added l-(fluorosulfonyl)-2,3-dimethyl-lH-imidazol-3-ium trifluoromethanesulfonate (1.13 g, 3.45 mmol) at RT. The reaction was stirred at RT. After 5 h, the title product was afforded as a solution. LC / MS (m / z): 674 [M+H],Preparation 28(S)-3-((tert-Butyldimethylsilyl)oxy)-N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-<7]pyrimidin-l(2H)-yl)-2- fluorophenyl)pyrrolidine- 1 -sulfonamide
[0210] To a solution of (S)-3-((tert-butyldimethylsilyl)oxy)pyrrolidine (138 mg, 687 pmol) in DCM (1 mL) was added TEA (86.9 mg, 858 pmol). Then, a solution of (3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-6?]pyrimidin-l(2H)-yl)-2-fluorophenyl)sulfamoyl fluoride (136 mg, 172 pmol) in DCM (2 mL) and DMF (0.5 mL) was added drop wise to the reaction, and the mixture was stirred at RT overnight. The reaction was concentrated, and the residue was purified by silica gel flash chromatography (0 to 100% EtOAc in heptanes). The appropriate fractions were concentrated to afford the title compound (47.5 mg, 32%) as a white solid. LC / MS (m / z): 855 [M+H],Preparation 293-Cyclopropyl-l-[2-fluoro-3-({methyl[(lR,2S)-2-((terL butyldimethylsilyl)oxy)cyclopentyl]sulfamoyl]amino)phenyl]-5-[(2-fluoro-4- iodophenyl)amino]-6,8-dimethylpyrido[4,3-r / ]pyri mi dine-2, 4, 7-trione
[0211] To a solution of l-(3-amino-2-chlorophenyl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3- ]pyrimidine-2,4,7(lH,3H,6H)-trione (130 mg, 214 pmol) in DCE (3 mL) were added CS2CO3 (209 nig, 642 pmol) and 1 -(fluorosulfonyl)-2,3-dimethyl-lH-imidazol-3-ium trifluoromethanesulfonate (140 mg, 428 pmol). The mixture was stirred at RT overnight. In a separate vial, to a solution of (lR,2S)-2-(( / -butyldimethylsilyl)oxy)-N-methylcyclopentan-l-amine (147 mg, 642 pmol) in DCM (2 mL) was added TEA (108 mg, 1.07 mmol). The first solution was added to the second reaction mixture. The mixture was stirred at RT for 1 h. then at 60 °C overnight. The reaction was concentrated and purified by silica gel flash chromatography (0 to 100% EtOAc in heptane). The appropriate fractions were concentrated to afford the title product (32 mg, 17%) as a white foam. LC7MS (m / z): 899 [M+H],Preparation 30l-[2-Fluoro-3-({[(lR,2S)-2-((tert- butyldimethylsilyl)oxy)cyclopentyl]sulfamoyl}amino)phenyl]-5-[(2-fluoro-4- iodophenyl)amino]-6,8-dimethylpyrido[4,3-r / ]pyrimidine-2, 4, 7-trione
[0212] To a solution of (17?,2S)-2-((tert-butyldimethylsilyl)oxy)cyclopentan-l -amine (150 mg, 696 pmol) in DCM (3mL) at -20 °C was added TEA (282 mg, 2.79 mmol), followed by SO2CI2 (IM in DCM) (282 mg, 2.09 mmol). The reaction was stirred at -20 °C for 30 min. In a separate vial, to a solution of l-(3-amino-2-chlorophenyl)-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-dJpyrimidine-2,4,7(lH,3H,6H)-trione (119 mg, 209 pmol) in DMF (3 mL) was added NaH (41.8 mg, 1.04 mmol). After 30 min, the first solution was added via a syringe to the second solution at 0 °C. The reaction was stirred overnight without replenishing the ice bath. The reaction was diluted with EtOAc and washed with H2O. The aq. layer was extracted with EtOAc (3x). The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel flash chromatography (0 to 100% EtOAc in heptane). The appropriate fractions were concentrated to afford the title compound (60 mg, 10%) as a pale -yellow foam. LC / MS (m / z): 845 [M+H],EXAMPLESExample 14-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)-N-(2-hydroxyethyl)benzenesulfonamide
[0213] To a stirred solution of 4-{[3-cyclopropyl-l-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxopyrido[2,3-d]pyrimidin-5-yl]amino]-N-(2-hydroxyethyl)benzenesulfonamide (40 mg, 0.06 mmol) in THF (4 mL) was added NaOCH3(54.35 uL, 0.30 mmol, 30% in MeOH) at 0 °C. The resulting mixture was stirred at 0 °C for 10 min under N2. The reaction was treated with EtOAc (100 mL). The mixture was washed with H2O (3 x 50 mL), saturated aq. NaCl solution (50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated to afford a residue. The residue was purified by prep-HPLC (XBridge Prep OBD C18 Column 30*150 mm, 5pm; H2O (aq lOmM NH4HCO3 + 0.05% NH3. H2O), ACN). The appropriate fractions were lyophilized to afford the title compound (13.9 mg, 34%) as a white solid. LC / MS (m / z): 682 [M+H],Example 2l-[2-Fluoro-3-({[2-hydroxyethyl](methyl)sulfamoyl}amino)phenyl]-5-[(2-fluoro-4- iodophenyl)amino]-3,6,8-trimethylpyrido[4,3-tZ]pyrimidine-2,4,7-trione
[0214] To a solution of l-(3-amino-2-fluorophenyl)-5-((2-fluoro-4-iodophenyl)amino)-3,6,8-trimethylpyrido[4,3-d]pyrimidine-2,4,7(lH,3H,6H)-trione (72 mg, 95% wt, 0.12 mmol) in DCE (2.0 mL) and DMF (0.3 mL) at RT was added l-(fluorosulfonyl)-2,3-dimethyl-lH-imidazol-3-ium trifluoromethanesulfonate (160 mg, 0.49 mmol). The mixture was stirred at RT for 3.5 hours. To the reaction was added EtsN (62 mg, 0.61 mmol) followed by 2-(methylamino)ethan-l-ol (37 mg, 0.49 mmol). The mixture was stirred at 60 °C for 1.5 hours. The reaction was loaded onto silica and purified by flash silica gel chromatography (0% tol00% [EtOAc-EtOH (3:1) in heptanes]. The appropriate fractions were combined and concentrated to give a white residue. The residue was purified by prep-HPLC (UPLC CSH C18 Column, 2.1*50 mm, 1.7pm; H2O (aq lOmM NH4HCO3), ACN). The desired fractions were combined and lyophilized to give the title compound (9.0 mg, 10 %, 95% Purity) as a white solid. LC / MS (m / z): 703 [M+H],
[0215] The compounds in the following table were prepared essentially as described in Example 2 using the appropriate aryl amine and alkyl amine.Example 53-Cyclopropyl-l-[2-fluoro-3-({[2-hydroxyethyl](methyl)sulfamoyl]amino)phenyl]-5-[(2- fluoro-4-iodophenyl)amino]-6,8-dimethylpyrido[4,3-<7]pyrimidine-2, 4, 7-trione
[0216] To a solution of l-(3-amino-2-fluorophenyl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3- d]pyrimidine-2,4,7(lH,3H,6H)-trione (500 mg, 0.85 mmol) in DCM (5 mL) and DMF (1 mL) was added 1- (fluorosulfonyl)-2,3-dimethyl-lH-imidazol-3-ium trifluoromethanesulfonate (1.11 g, 3.38 mmol) and triethylenediamine (569 mg, 5.07 mmol). The mixture was stirred at RT for 2 hours then calcium di[bis(trifluoromethanesulfonyl)imide] (1.02 g, 1.69 mmol) was added followed by a solution of 2-(methylamino)ethan-l-ol (191 mg, 2.54 mmol) in DCM (1 mL). The mixture was stirred at RT for 18 hours then concentrated in vacuo. The residue was purified by prep-HPLC (UPLC CSH C18 Column, 2.1*50 mm, 1.7pm; H2O (aq lOmM NH4HCO3), ACN). The appropriate fractions were combined and concentrated then lyophilized overnight to give the title compound as a white solid. LC / MS (m / z): 729 [M+H],
[0217] The compounds in the following table were prepared essentially as described in Example 5 using the appropriate aryl amine and alkyl amine.Example 30N-(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido [4,3 -d]pyrimidin- 1 (2H)-yl)-2-fluorophenyl)-3 -hydroxyazetidine- 1 - sulfonamide
[0218] To a solution of (3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)-2-fluorophenyl)sulfamoyl fluoride (136 mg, 172 pmol) in DCM (1 mL) were added to a solution of azetidin-3-ol (37.6 mg, 515 pmol) and TEA (86.9 mg, 120 pL, 858 pmol) in DCM (2 mL). The reaction mixture was stirred overnight. The reaction mixture was concentrated and purified by reverse phase HPLC (C18, 0% to 50% lOmM aq. NH4HCO3, 5% MeOH / ACN) to afford the title compound (40 mg, 55 pmol, 32%) as a white solid. LC / MS (m / z): 727 [M+H],Example 31N-(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)-2-fluorophenyl)-4-hydroxybenzenesulfonamide
[0219] To a solution of l-(3-amino-2-fluorophenyl)-3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7(1H,3H,6H)-trione (91.9 mg, 140 pmol) in pyridine (1.0 mL) was added 4-hydroxybenzenesulfonyl chloride (53.9 mg, 280 pmol) followed by DMAP (2.56 mg, 21.0 pmol). The mixture was stirred at RT for 30 min. The reaction was quenched by the addition of HC1 (IN aq., 10 mL), and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with saturated aq. NaCl solution, dried over Na2SO4, filtered, and concentrated. The residue was purified by prep-HPLC (XSelect CSH C18 column, 40 to 95% ACN in H2O, with 0.1% FA). The appropriate fractions were lyophilized to give a residue which was further purified by silica gel flash chromatography (0 to 50% EtOAc / EtOH (3:l / v:v) in heptanes). The appropriate fractions were concentrated to afford the title compound (41.0 mg, 37 %) as a white solid. LC / MS (m / z): 748 [M+H],Example 323-Chloro-4-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo- 3,4,6,7-tetrahydropyrido[4,3-<7]pyrimidin-l(2H)-yl)-N-(2-hydroxyethyl)benzenesulfonamide
[0220] To a stirred mixture of 3-cyclopropyl-l-(2-fluoro-4-iodophenyl)-6,8-dimethyl-2,4,7-trioxopyrido[2,3-d]pyrimidin-5-yl trifluoromethanesulfonate (200 mg, 0.33 mmol) and 4-amino-3-chloro-N-(2-hydroxyethyl)benzenesulfonamide (163 mg, 0.65 mmol) in THF (5 mL) was added LiHMDS (1.625 mmol, IM in THF) dropwise at 0 °C under N2. The resulting mixture was stirred at RT for 1 h under N2. The reaction was quenched by the addition of H2O (0.7 mL) at 0 °C. The mixture was diluted with EtOAc (50 mL). The mixture was washed with H2O (2 x 30 mL), saturated aq. NaCl solution (30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated. The residue was purified by reversed-phase flash chromatography (column, C18; ACN in H2O (0.1% NH3 H2O)). The appropriate fractions were concentrated to afford the title compound (62.4 mg, 27%) as a white solid. LC / MS (m / z): 716 [M+H],Example 333-Cyclopropyl-l-[2-fluoro-3-({[cis-2-hydroxycyclobutyl](methyl)sulfamoyl}amino)phenyl]- 5-[(2-fluoro-4-iodophenyl)aminol-6,8-dimethylpyrido[4,3-r / lpyrimidine-2, 4, 7-trione
[0221] To a stirred solution of cis-3-cyclopropyl-l-[2-fluoro-3-({methyl[2-(oxan-2-yloxy)cyclobutyl]sulfamoyl}amino)phenyl]-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethylpyrido[4,3-d]pyrimidine-2,4,7-trione (racemic mixture) (20 mg, 0.02 mmol) in EtOH (2 mL) was added concentrated HC1 (0.5 mL) dropwise at 0 °C under N2. The mixture was stirred at RT for 6 h under N2. The reaction was concentrated. The residue was purified by Prep-HPLC (XB ridge Shield RP18 OBD column, 30*150 mm, 5pm; Mobile Phase A: H2O (10 mM NH4HCO3+ 0.05% NH3H2O), Mobile Phase B: ACN). The appropriate fractions were lyophilized to afford the title compound (6 mg, 33%) as a white solid. LC / MS (m / z): 755 [M+H],Example 343-Cyclopropyl-l-[2-fluoro-3-({[2-hydroxyethyl]sulfamoyl]amino)phenyl]-5-[(2-fluoro-4- iodophenyl)amino]-6,8-dimethylpyrido[4,3-r / ]pyrimidine-2,4,7-trione
[0222] To a solution of 3-cyclopropyl-l-[2-fhioro-3-({[((tert-butyldimethylsilyl)oxy)ethyl]sulfamoyl]amino)phenyl]-5-[(2-fluoro-4-iodophenyl)amino]- 6, X-dimethylpyrido[4,3-d]pyrimidine-2,4,7-trione (34.2 mg, 41.3 pmol) in THF (2 mL) at 0°C was added TBAF (IM in THF) (32.4 mg, 124 pmol). The ice bath was removed, and the reaction was stirred at RT for 1 h. The reaction was diluted with DCM (5 mL) and washed with saturated aq. NH4CI solution (5 mL). The aq. layer was extracted with DCM (5 mL). The combined organic layers were dried over Na2SC>4, filtered and concentrated. The material was purified by silica gel flash chromatography (0% to 100% EtOAc-EtOH (3:l / v:v) in heptanes). The appropriate fractions were concentrated to afford the title compound (27 mg, 87 %) as a white solid. LC / MS (m / z): 715 [M+H],
[0223] The compounds in the following table were prepared essentially as described in Example 34 using the appropriate TBS protected alcohol.Example 42N-(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido [4,3 -d]pyrimidin- 1 (2H)-yl)-2-fluorophenyl)-3 -hydroxypropane- 1 - sulfonamide
[0224] To a solution of 3-(N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-l(2H)-yl)-2-fluorophenyl)sulfamoyl)propyl acetate (56 mg, 44 pmol) in THF (2.5 mL) and MeOH (0.5 mL) was added LiOH·H2O (5.6 mg, 133 pmol). The mixture was stirred at RT for 3 h. The reaction was concentrated under a stream of N2. The residue purified by prep-HPLC (XSelect CSH Cl 8 column, 5% to 95% ACN in H2O, with 0.1% FA). The appropriate fractions were lyophilized to afford the title compound (24 mg, 73 %) as a white solid. LC / MS (m / z): 714 [M+H],Example 433-Cyclopropyl-l-[2-fluoro-3-({[2-hydroxycyclobutyl](methyl)sulfamoyl}amino)phenyl]-5- [(2-fluoro-4-iodophenyl)amino]-6,8-dimethylpyrido[4,3-<i]pyrimidine-2,4, 7-trione, Isomer 1
[0225] The racemic mixture of 3 -cyclopropyl- l-[2-fluoro-3-({ [2-hydroxycyclobutyl](methyl)sulfamoyl}amino)phenyl]-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethylpyrido[4,3-Z]pyrimidine-2, 4, 7-trione (100 mg) was isolated by chiral HPLC (CHIRAL ART Cellulose-SC column, 3*25 cm, 5 pm; MTBE (0.1% DEA), EtOH / THF=1:1). The first eluting isomer was concentrated and lyophilized to afford the title compound (26 mg, 26%) as a white solid. LC / MS (m / z): 755 [M+H],Example 443-Cyclopropyl-l-[2-fluoro-3-({ [2-hydroxycyclobutyl](methyl)sulfamoyl]amino)phenyl]-5- [(2-fluoro-4-iodophenyl)amino]-6,8-dimethylpyrido[4,3-rZ]pyrimidine-2, 4, 7-trione, Isomer 2
[0226] The racemic mixture of 3-cyclopropyl-l-[2-fluoro-3-({[2-hydroxycyclobutyl](methyl)sulfamoyl]amino)phenyl]-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethylpyrido[4,3-r / ]pyrimidine-2, 4, 7-trione (100 mg) was isolated by chiral HPLC (CHIRAL ART Cellulose-SC column, 3*25 cm, 5 pm; MTBE (0.1% DEA), EtOH / THE= 1:1). The second eluting isomer was concentrated and lyophilized to afford the title compound (34 mg, 34%). LC / MS (m / z): 755 [M+H],LS513 (Colorectal Carcinoma) Spheroid Proliferation Inhibition Assay in The Presence and Absence of Efflux inhibition
[0227] The purpose of this assay is to measure the antiproliferative activity of test compounds against LS513 (ATCC: CRL-2134) colorectal carcinoma cells grown as 3D spheroids in the presence or absence of the efflux pump inhibitor, elacridar. The differences between the elacridar treated and compound only condition was used to indicate the potential of test compounds to be efflux substrates.
[0228] Assay plates were prepared by pre-spotting compounds in DMSO into Coming® Spheroid microplates in a 1:3 10-point dilution series with a final concentration range of 10 nM (highest) to 0.5 pM using an ECHO 655 Acoustic Liquid Handler (Beckman LifeSciences). To establish the effect of the efflux inhibitor, elacridar, a copy of the dose response plate was prepared in which a constant concentration of 438 nM elacridar was spiked across the entire plate. This concentration of elacridar has no effect on cell viability or growth in this assay.
[0229] To perform the assay, adherent cells were separated from cell culture surfaces using TrypLE™ Express Enzyme. A single cell suspension was prepared by passing cells through a 40 pm cell strainer. Cell suspensions were stained with ViaStain™ AOPI Staining Solution and counted using a Cellometer™ K2 fluorescent cell counter (Revvity). Cells were then diluted to a density of 25000 live cells / mL in complete cell growth medium (Roswell Park Memorial Institute (RPMI) with 10% Fetal Bovine Serum (FBS) and Penicillin G / Streptomycin supplementation - Gibco). Cell suspensions were dispensed into assay-ready microplates using a WELLJET Reagent Dispenser (INTEGRA Biosciences). Cells were seeded at a density of 1000 cells / well. Plates were sealed with Breathe-Easy® sealing membranes (Diversified Biotech), transferred to a 37°C incubator with 5% CO2, and allowed to incubate for 4 days. The final volume in the assay was 40 pL and the final concentration of DMSO was 0.19%.
[0230] ATP was measured to assess cell viability using the CellTiter-Glo® (CTG) 2.0 Cell Viability Assay (Promega) following the manufacturer’s protocol with the described modifications. The CTG protocol was adapted to the 3D format by shaking the plates for 10 minutes at 1000 RPM, followed by a 5-minute centrifugation at 300 RPM. Plates were allowed to stabilize at room temperature for 10 minutes before luminescence was read using a PHERAstar FSX Multimode Plate reader (BMG LABTECH).
[0231] Raw luminescence data obtained by CTG assay were analyzed using Genedata Screener® 20.0.5. Within the program, data were normalized to the average signal from 32 wells treated with the positive control (50 nM Trametiglue) and the average signal from 32 wells treated with the negative control (0.19% DMSO) to calculate the % Activity of the compound:...,- rtz (treated value— positive control),,% Activity = lOOx (1 - - - - - —) eq. 1(negative control-positive control)
[0232] % Activity values were fit to a four-parameter non-linear regression in GenedataScreener® 20.0.5. to determine IC50 values.
[0233] IC50 values obtained from the elacridar containing condition were compared to those obtained in the absence of elacridar to establish an efflux ratio for the test compound.
[0234] The compounds of Examples 1-44 were tested in the LS513 assay in the presence and absence of elacridar. Results are shown below in Table 1.Table 1
Claims
WE CLAIM:
1. A compound of the formula:or a pharmaceutically acceptable salt thereof; whereinR1is hydrogen, C1-C3 alkyl, or C3-C5 cycloalkyl;RA1and RA3are independently selected from halogen;RC1is fluoro or chloro;Rcis hydrogen, halogen, or C1-C3 alkyl;X3is a group of the formula:Z1and Z2are independently selected from O and NH;RX3is hydrogen or C1-C3 alkyl;RX4is hydrogen, C1-C3 alkyl, C1-C3 hydroxyalkyl, or C1-C3 alkoxy-Ci-Cs-alkyl; orRX3and RX4together with the atoms to which they attach form a 5- to 6-membered monocyclic heterocyclyl; andRX5is Ci-Ce hydroxyalkyl, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C3-C10 cycloalkyl, 3-to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, Ce-Cio aryl, 5- to 10-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, C3-C10 cycloalkyl-Ci-Cs-alkyl, 3- to 10-membered heterocyclyl-Ci-Cs-alkyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, Ce-Cio aryl-Ci-C -alkyl, or 5- to 10-membered heteroaryl-Ci-Cs-alkyl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, and heteroarylalkyl are substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-Cs-hydroxyalkoxy-Ci-Cb-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, and heteroarylalkyl are optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, Ci-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl; orRX4and Rx5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-Cs-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, and wherein the heterocyclyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, Ci-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having the formula:
3. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, having the formula:
4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R1is hydrogen, methyl, or cyclopropyl.
5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein RA1is fluoro and RA3is iodo.
6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein RC1is fluoro.
7. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein RC1is chloro.
8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein X3is a group of the formula:
9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein RX3is hydrogen.
10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein RX4is hydrogen or methyl.
11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein RX4is hydrogen.
12. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein RX4is methyl.
13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein Rx5is Ci-Ce hydroxyalkyl, Ci-Cs-hydroxyalkoxy-Ci-Cs-alkyl, C3-C10 cycloalkyl, 3- to 10-membered heterocyclyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, Ce-Cio aryl, 5- to 10-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, C3-C10cycloalkyl-Ci-Cs-alkyl, 3- to 10-membered heterocyclyl-Ci-Cs-alkyl containing 1, 2, 3, or 4 ring heteroatoms independently selected from N, O, and S, Ce-Cio aryl-Ci-C.3-alkyl, or 5- to 10-membered heteroaryl-Ci-Ca-alkyl containing 1, 2, or 3 ring heteroatoms independently selected from N, O, and S, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, and heteroarylalkyl are substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-C3-hydroxyalkoxy-Ci-C3-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, and heteroarylalkyl are optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, Ci-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl.
14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein RX5is Ci-Ce hydroxyalkyl.
15. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein RX5is C3-C10 cycloalkyl substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, Ci-Cs-hydroxyalkoxy-Ci-Cs-alkyl, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, wherein the cycloalkyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, C1-C3 halothioalkoxy, and C1-C3 alkoxy-Ci-Cs-alkyl.
16. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein RX5is a group of the formula:
17. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein RX4and Rx5together with the nitrogen atom to which they are attached form a 4- to 10-membered heterocyclyl optionally containing 1, 2, or 3 further ring heteroatoms independently selected from N, O, and S, wherein the heterocyclyl is substituted by hydroxy, C1-C3 hydroxyalkyl, C1-C3 hydroxyalkoxy, C1-C3 hydroxythioalkoxy, or C1-C3 hydroxyalkylcarbonyl, and wherein the heterocyclyl is optionally further substituted by 1, 2, or 3 substituents independently selected from halogen, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy-Ci-Ca-alkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C1-C3 thioalkoxy, and C1-C3 halothioalkoxy.
18. The compound of claim 17, or a pharmaceutically acceptable salt thereof, wherein RX4and Rx5together with the nitrogen atom to which they are attached form a group of the formula:
19. The compound of claim 1, selected from:14614814915020. A pharmaceutical composition comprising a compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
21. A method of treating cancer, comprising administering to a patient in need thereof, a therapeutically effective amount of a compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof.
22. The method of claim 21, wherein the cancer is associated with dysregulation of the MAPK7 ERK pathway.
23. The method of claim 21 or claim 22, wherein the cancer is hematological cancer,lymphoma, myeloma, leukemia, neurological cancer, skin cancer, breast cancer, prostate cancer, colorectal cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, genitourinary cancer, bone cancer, renal cancer, or vascular cancer.
24. The method of claim 21 or claim 22, wherein the cancer is non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), uterine carcinoma, endometrial carcinoma, bladder cancer, esophageal cancer, thyroid cancer, melanoma, multiple myeloma, acute myeloid leukemia (AML), low-grade serous ovarian cancer, neurofibroma, or glioma.
25. A compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, for use in therapy.
26. A compound of any one of claims 1-19, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.
27. The compound or pharmaceutically acceptable salt thereof for use of claim 26, wherein the cancer is associated with dysregulation of the MAPK / ERK pathway.
28. The compound or pharmaceutically acceptable salt thereof for use of claim 26 or claim 27, wherein the cancer is hematological cancer, lymphoma, myeloma, leukemia, neurological cancer, skin cancer, breast cancer, prostate cancer, colorectal cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, genitourinary cancer, bone cancer, renal cancer, or vascular cancer.
29. The compound or pharmaceutically acceptable salt thereof for use of claim 26 or claim 27, wherein the cancer is non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), uterine carcinoma, endometrial carcinoma, bladder cancer, esophageal cancer, thyroid cancer, melanoma, multiple myeloma, acute myeloid leukemia (AML), low-grade serous ovarian cancer, neurofibroma, or glioma.
